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Abstract 
 
 
The aim of this thesis is to evaluate the extent to which cost-effectiveness of a recently 
launched drug in the treatment of overactive bladder is supported by real world 
evidence. The demand for real world effectiveness data by Payers and decision-makers 
is increasing to better manage the uncertainty at the time of making reimbursement 
decisions. Real world data can help to fill the knowledge gap between clinical trials and 
actual clinical practice. 
Overactive bladder is one of many chronic conditions likely to impact people as they 
age. It is a common condition characterised by a group of lower urinary tract storage 
symptoms, which has a profound and measurable negative effect on patient health-
related quality of life (HRQoL). The economic burden of OAB is also considerable.  
Antimuscarincs have been the mainstay pharmacological treatment for OAB for over 
30 years, but adverse events and persistence on medication remain a key issue. 
Mirabegron, a ß3 adrenoceptor agonist provides an alternative option.  
The thesis presents and critiques 9 peer-reviewed publications to demonstrate the 
value evidence generated pre-health-technology assessment (HTA) and that generated 
post-health -technology assessment in clinical practice. Each publication adds a new 
building block to the value proposition, and a sophistication of methods that help 
illustrate the value of the new drug compared to competing alternatives. 
The impact of OAB on patient HRQoL is explored through analyses of both disease 
specific and generic validated patient reported outcome (PRO) instruments. Utility 
values are also derived for the purposes of health economic modelling. The 
comparison of efficacy and safety of mirabegron with other competing alternatives is 
assessed using network meta-analysis (NMA), a requirement from most HTA bodies in 
the absence of head-to-head evidence.  The outputs from the NMA and the PRO 
analyses are then applied to a series of trial based and NMA based HE models to assess 
the cost-effectiveness of mirabegron. This is followed by an assessment of 
effectiveness through analysis of a large retrospective database to see if indeed cost-
effectiveness is supported in the clinical practice.  
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The thesis concludes that cost-effectiveness of mirabegron is broadly supported by 
Real world evidence in terms of persistence and adherence while also highlighting the 
strengths and weaknesses of the current research and making recommendations for 
future research.  
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Chapter 1:   Introduction 
 
1.1   The Role of Real World Evidence (RWE) in Drug Development and  
Commercialisation 
 
Real world evidence (RWE) is becoming an increasingly important component of Bio-
pharmaceutical drug development and commercialization. There is a growing demand 
from regulators, public and private payers and prescribers for broader information on 
real-world effectiveness and safety in order to better understand the impact of the 
new product in the real-world setting. As a result, plans to generate RWE are being 
included earlier in the research and development phase of new drugs (Annemans et al., 
2007). 
This demand for RWE is driven by the unsustainable cost explosion in major healthcare 
systems, resulting in cost-containment measures and a more demanding 
reimbursement environment which continues to raise the bar with respect to evidence. 
This has also been compounded by the growing emergence of health technology 
assessments (HTA) in many healthcare systems (Volker et al., 2014). An example of the 
greater scrutiny placed on demonstrating value can be seen with the United Kingdom 
(UK) HTA body, National Institute of Clinical Excellence (NICE). Between March 2000 
and April 2014, NICE gave a  negative recommendation for 36 out of 141 single 
technology appraisals (rejection rate of 26%) and the rejection rate for new oncology 
products was higher at 42% (24/57) (Volker et al., 2014).  
Another example of the HTA effect is Germany’s Act on the Reform of the Market for 
Medicinal Products (AMNOG) which between Jan 2011 and December 2013 assessed 
51 out of 62 products to have less than significant incremental benefit, a rejection rate 
of 82% (Volker et al., 2014). These developments are leading to increased demand for 
demonstration of impact in the real world setting and the level of that impact may also 
influence varying payments for different patient subgroups, potentially leading to a 
more outcomes based paradigm shift. Therefore, while Regulatory authorities may for 
example require post-approval studies to determine the safety of the new product 
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when it is widely prescribed, payers require validation of a products real-world clinical 
effectiveness and cost-effectiveness to make more informed decisions on 
reimbursement, pricing and formulary placement  (Christel M., 2014; Annemans et al., 
2007). 
Data generated from real-world patient experience can potentially help in 
understanding how to incorporate new technologies in to clinical practice. In doing so 
it can help to improve the quality and delivery of medical care, reduce overall costs 
and improve outcomes. These are essentially data to help fill the knowledge gap 
between clinical trials and actual clinical practice. There are several other reasons why 
the push towards real-world evidence is happening so quickly. Randomized controlled 
trials (RCTs) although they form the ‘gold standard’ for establishing efficacy and 
gaining regulatory approval, this is in an idealised environment and can often only 
measure efficacy in a limited population, thereby not providing a true indication of 
effectiveness (Cziraky, 2014). More information may also be required on how drugs 
perform in the real-world in specific subgroups such as age, gender, patient with co-
morbid conditions, disease severity (Figure 1). Real-life data can provide insights that 
are not usually provided by RCTs such as epidemiology, adherence, compliance and 
cost and healthcare resource utilization insights (Cziraky, 2014). Finally, and more 
importantly payers are taking more of an interest in real world effectiveness data to 
better manage the uncertainty at the time of making reimbursement decisions 
(Annemans et al., 2007).  
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Figure 1: Real-world evidence studies: Applied Clinical Trials. (Adapted fromCziraky 
Mark, Pollock Michael. http://www.appliedclinicaltrialsonline.com/real-world-evidence-studies) 
 
An increased demand for robust evidence has led to the integration of Health 
economics and outcomes research (HEOR) within traditional Research and 
Development (R&D), impacting clinical trial design and the management of economic 
endpoints within these trials. HEOR generates evidence of the economic value of new 
and existing products and helps decision-makers and payers determine reimbursement 
policies and insurance coverage for new and existing therapies. A growing number of 
Phase III trials now include economic endpoints and analyses, alongside the clinical 
outcome measures, to demonstrate the cost-effectiveness of new products 
(Annemans et al, 2007). 
Therefore, from a HEOR perspective there are obvious benefits of working on real life 
or observational data before launch of a new product. Reimbursement authorities at 
pre-launch are always asking for more evidence with respect to cost-effectiveness in 
the real world but the industry argues that this is not possible given that the product is 
not available until a decision on its reimbursement is reached. As a result 
Populations Studied 
utilisation 
The cone of evidence development is changing Variances in 
populations utilising 
technology versus the 
populations studied. 
• Age, gender, 
race 
• Co-
morbidities 
• Poly-
pharmacy 
• Lifestyle 
variations e.g. 
smoking 
• Severity of 
disease 
  
Phase I - III Post approval  
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reimbursement authorities will accept or even request Health Economic modeling. The 
modeling is based on different available evidence, observational data and RCT data. In 
addition to this some payers may approve conditionally pending collection of real-
world data post-launch for validation (Cziraky, 2014).  This is however not common 
practice in all countries and in countries where HE modeling or modeling assumptions 
are not accepted reimbursement and pricing negotiations may be negatively impacted. 
It is therefore important that the opportunity to collect real-world data post launch is 
fully utilized. This will not only help to validate modeling assumptions, but also 
provides the opportunity to prove effectiveness in a large pragmatic trial against key 
competitors which addresses outcomes such as adherence, persistence and other 
relevant long-term outcomes. Finally, it will also enable us to assess the value of a 
range of treatments options and evaluate the changing environment (Figure 2) 
(Annemans et al., 2007). 
 
 
 
 
 
  
 
 
 
 
 
Figure 2: Phases of HEOR (adapted from https://www.ispor.org/News/articles/Oct07/RLD.asp) 
 
Early development Demonstrate value Launch Medical Practice 
 Burden/cost of disease 
 HE modelling (1) 
 Patient care management 
 Cost benefit; cost effectiveness; cost 
utility 
 Quality of life 
 Budget Impact 
 HE modelling 
 
 Epidemiology 
 Medical care 
practice 
 Published 
HEOR studies 
 Published 
clinical studies 
 
 Post-launch 
observational 
studies 
Retrospective and 
prospective 
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As stated before, managing uncertainty for payers and decision makers during 
reimbursement processes is essential. RWE supporting effectiveness can help manage 
this to some extent and therefore is becoming a vital component of the body of 
evidence submitted by the pharmaceutical industry pre and post launch.  
With an ageing population as one of the major factors impacting health care spending, 
effective management of chronic conditions will become a major priority for 
healthcare systems across the world (Kaplan et al., 2004).  RWE will therefore play an 
instrumental part in helping payers to make difficult decisions when allocating 
resources. Overactive bladder (OAB) is one of many chronic conditions likely to impact 
people as they age. However, while there is considerable evidence that OAB has a 
significant humanistic and economic burden (Coyne et al., 2011b; Hawken et al., 2016; 
Sung et al., 2012) due to the non-life threatening nature of the disease there is a 
danger that it could fall below the radar and down the list of priorities when compared 
to conditions such as heart disease and diabetes. It is therefore vital that strategies are 
put in place to generate evidence to highlight the humanistic burden placed on 
patients suffering from this disease, and fill the current gap in cost-effectiveness and 
real world effectiveness data for pharmacological treatments used in the treatment of 
OAB. 
OAB has a profound and negative impact on patient health-related quality of life 
(HRQoL) (Coyne et al., 2011b) and poses considerable economic burden (Irwin et 
al.,2009). For the past 30 years, anitmuscarinics have been the mainstay in terms of 
pharmacological interventions. However, although with established efficacy (Buser et 
al, 2012; Nabi et al., 2006), antimuscarinic agents have several limitations which 
include unwanted adverse events and high rates of discontinuation (Oefelein et al., 
2011). Mirabegron, a β3-adrenergic agonist is the first new class of treatment in OAB in 
over 30 years. It has a mechanism of action that is distinct from antimuscarinics and 
therefore is associated with a lower incidence of antimuscarinic related adverse events 
such as dry mouth and constipation (Khullar et al., 2015). Economic analyses of 
Mirabergon have not been available in literature prior to the publications submitted in 
this thesis. Previous cost-effectiveness analyses have been predominantly focussed on 
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antimuscarinic agents, and have mainly centred on data from clinical trials (Aballea et 
al., 2015). There has been very little emphasis on demonstrating cost-effectiveness in 
the real world setting. 
 
1.2   Aims of the Thesis 
The aim of the present thesis therefore, was to firstly, demonstrate the cost-
effectiveness of Mirabegron in the pre-HTA submission phase. Secondly, to assess the 
extent to which cost-effectiveness of Mirabegron is supported using RWE. The overall 
aim is to try and reduce the uncertainty in value demonstration between clinical trial 
and clinical practice.  
The thesis will achieve this aim through the presentation of nine published papers, for 
which the present author was either a first author or co-author. Two major themes are 
included in the body of work (Figure 3): 
1. Predictive assessment of value pre-HTA assessment (pre-launch) 
2. Real world assessment post-HTA assessment (post-launch) 
 
The predictive assessment of value essentially includes research that would normally 
be assessed by a HTA body such as NICE for a single technology appraisal while the 
RWE evidence includes the post HTA assessment (post-launch) that assesses the 
effectiveness of the drug in clinical practice. The thesis will provide strengths and 
limitations of the evidence generated to support the predictive and real world 
assessment, and try to evaluate the extent to which they support each other. Finally, 
this thesis will try to draw plausible conclusions and make recommendations on areas 
where future research may be focussed.  
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1.3   Structure of the Thesis 
1.3 Overview of the Thesis 
Chapter 1 provides an overview of the evidence requirements at the various stages of 
drug development. This chapter is particularly focussed on the increasing demand for 
RWE by payers and HTA bodies, to better manage the uncertainty at the time of 
making reimbursement decisions. General aims and structure of the thesis are also 
included.  
Chapter 2 will provide a comprehensive background to OAB in terms of definitions, 
epidemiology, humanistic and economic burden, current treatment guidelines and 
treatment options. It also introduces Mirabegron, the latest option in pharmacological 
treatments in OAB. 
Chapter 3 is focussed on patient reported outcomes (PROs) in OAB. The impact of OAB 
treatments on health-related quality of life (HRQoL) is discussed through research 
conducted using both generic and disease-specific instruments. The strength and 
limitations of both approaches is highlighted. 
 
Uncertainty 
Uncertainty 
Predictive 
Pre-launch/HTA 
Real World Evidence 
Post-launch/HTA  
Value 
Figure 3: Summary of predcitve assessment pre-HTA and post-HTA assessment  
RCT = Randomized Controlled Trial, SLR= systematic literature review, RWE= real world evidence, CEA = Cost-effectiveness 
analysis, CUA = Cost-utility analysis 
*represents evidence (peer-reviewed publications) that have been submitted in this thesis 
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Chapter 4 discusses the importance of comparative effectiveness to payers. The 
network meta-analysis comparing efficacy and safety of treatment for OAB is 
introduced, and how this adds to previous literature reviews and meta-analyses. 
Strengths, limitations and application of this research are also discussed. 
In Chapter 5, a critique of health economic modelling in OAB is provided. The learning 
from this is then applied to two different approaches to health economic modelling in 
OAB. This approach modelled progression of OAB symptoms separately, pays more 
attention to the treatment pathways and treatment sequences in OAB.  
Chapter 6 introduces the persistence and adherence to OAB medications using RWE. In 
this chapter the methodology, results and interpretation of a large UK retrospective 
database study are discussed. A HE model developed using the main outputs of this 
study provides the basis of further discussion on the economic impact of persistence 
and adherence. The model also allows for broad comparisons between HE modelling 
described in Chapter 5 (pre-launch).  
Chapter 7 presents a summary, conclusions, and recommendations for future research. 
In this chapter the extent to which RWE supports cost-effectiveness established 
previously (pre-launch and pre-HTA) is discussed along with the associated limitations. 
Areas for future research that would complement the current thesis are also 
highlighted.   
 
 
Chapter 2:  Background of OAB 
2.1    Introduction 
Chapter 1 has already examined the growing need for RWE to support effectiveness 
and focussed attention on the need for such evidence as well as cost-effectiveness 
evidence to support pharmacological interventions in OAB. Chapter 2 aims to provide 
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some more background on overactive bladder in terms of definitions, epidemiology, 
humanistic and economic burden, current treatments, guidelines and challenges.  
2.2   Definition of Overactive Bladder 
Overactive bladder (OAB) is a common condition characterised by a group of lower 
urinary tract storage symptoms. The condition is defined by the International 
Continence Society (ICS) as a disorder involving urgency, with or without urge 
incontinence, usually with frequency and nocturia in the absence of proven infection 
or other obvious pathology (Abrams et al., 2003). The ICS definition of OAB is widely 
applied and accepted. ICS definitions for each of the four lower urinary tract symptoms 
that make up OAB are shown in Table 1 (Abrams et al., 2003). OAB is sometimes 
further categorised as OABwet, which is OAB that occurs with urinary incontinence, and 
OABdry, that is OAB without urinary incontinence (NICE 2013). It is estimated that 
approximately 30% of those affected with OAB have OABwet and 70% have OABdry 
(Tikkinen et al., 2007; Wen et al., 2014). 
Table 2.1 Definitions of the lower urinary storage symptoms that constitute OAB 
Symptom Definition 
Urgency Sudden compelling desire to pass urine which is difficult to 
deter 
Increased daytime 
frequency 
Voiding too often by day 
Nocturia Waking at night one or more times to void 
Urge urinary 
incontinence 
Involuntary leakage accompanied by, or immediately 
preceded by, urgency 
 
Source: Adapted from Abrams et al. (2003) 
2.3   Epidemiology of OAB 
In large population-based or community-based studies conducted in Europe, North 
America, South America and Asia, estimates of the prevalence of OAB ranged from 
2.1% to 24.7%; most estimates were within the range of 12% to 19% (Table 2.2). No 
population-based estimates for the prevalence of OAB are currently available for 
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Australia or Africa (Corocos et al., 2004; Coyne et al., 2008; Coyne et al., 2011a; Coyne 
et al., 2011b; Coyne et al.,2012b; Coyne et al., 2013b). 
Table 2.2: Prevalence of OAB in large population-based or community-based surveys 
that included both sexes (>800 respondents) 
Reference Country 
Respondents, 
n 
Age range, 
yr 
OAB 
prevalence, 
% 
Europe     Irwin (2006a) Germany, Italy, Sweden, UK, Canada 19,165 18–≥70 11.8 Milsom (2001) France, Germany, Italy, Spain, Sweden, UK 16,776 40–≥75 16.6 Tikkinen (2007) Finland 3727 18–79 8.4a 
North America     Corcos 2004 Canada 3249 35–≥75 18.5 Coyne 2011a United States 20,000 40–95 24.7b Herschorn 2008 Canada 1000 18–90 13.9 Stewart 2003 United States 5204 18–≥75 16.5 
South America     Teloken 2006 Brazil 848 15–55 18.9 
Asia     Homma 2005 Japan 4570 40–100 12.4 Lee 2011a Korea 2000 18–96 12.2 Wang 2011 China 14,844 18–≥70 6.0c Wen 2014 China 9805 40–≥70 2.1 Yu 2005 Taiwan 1827 30–79 18.2 
a Age-standardised estimate. 
b OAB symptoms reported as occurring at least “often”. 
c Weighted for age, gender, and city size. 
 
Modelled data from one the largest population-based surveys of urinary incontinence, 
overactive bladder and other lower urinary tract symptoms (EPIC study) suggest that 
OAB burden is expected to increase because of population growth and ageing of the 
18 
 
population. The greatest increases are projected in Africa (31.1% increase from 2008 
to 2018), followed by South America (22.4%), Asia (22.1%), North America (18.4%) and 
Europe (4.4%30). Overall, an estimated 500 million individuals worldwide were affected 
by OAB using the ICS definition in 2013, which is anticipated to increase to 546 million 
by 2018 (20.1% increase) (Irwin et al., 2011). 
2.4   Burden of OAB 
2.4.1   Quality of Life and Work Productivity 
OAB symptoms have a profound and measureable negative effect on patient health-
related quality of life (HRQoL). Adults with OAB have statistically significantly lower 
scores on recognised generic HRQoL instruments such as short-form (SF)-36 and 
EuroQol 5-Dimensions (EQ-5D)] compared with matched controls (Coyne et al., 2008). 
Lower scores on both instruments indicate poorer quality of life. 
HRQoL impairment is influenced by the degree of symptom bother. In the EpiLUTS 
study, SF-12 mental and physical component summary scores were significantly lower 
(indicating worse HRQoL) for respondents with OAB symptom bother versus those 
with no/minimal symptoms or with OAB without symptom bother (Coyne et al.,2011b; 
Milsom et al., 2012).  
HRQoL scores are also negatively affected by the presence of urinary incontinence, 
with respondents with OAB and urge incontinence reporting lower HRQoL scores than 
those without urge incontinence (Milsom et al., 2012; Stewart et al., 2003; Tang et al., 
2012). Further, an increasing number of incontinence episodes per day were 
significantly associated with reduced scores on both generic and disease-specific 
HRQoL instruments in patients with OAB (Lee et al., 2011a).  
OAB symptoms increase the likelihood of affective disorders when compared with 
controls. Individuals with OAB had significantly higher scores on the Centre for 
Epidemiologic Studies Depression Scale (CES-D) than matched controls (Stewart et al., 
2003). In the EPIC study, a clinically elevated CES-D score of ≥21 was reported in 11.4% 
of OAB cases compared with 3.6% of matched controls (p < 0.001) (Coyne et al., 2008). 
Similarly in the EpiLUTS study, significantly higher rates of anxiety and depression, 
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defined as Hospital Anxiety and Depression Scale (HADS) scores ≥8, were reported in 
those with OAB compared with those with no or minimal OAB symptoms (Coyne et al., 
2011b; Milsom et al., 2012).  
 
In terms of productivity, data from several large surveys conducted in Europe and the 
US indicate that OAB symptoms affect employment status. Individuals with OAB were 
less likely to be employed (i.e. full-time, part-time or other paid work) compared with 
matched controls or compared with those with no or minimal symptoms; the 
differences between groups were statistically significant in most analyses (Coyne et al., 
2008; Coyne et al., 2012b; Sexton et al.,2009). 
2.4.2    Cost of Illness 
A summary of cost-of-illness studies, which estimate the overall economic burden of 
OAB in different countries and regions, is presented in Table 3. All study estimates 
were dependent on prevalence data, which may explain some of the variability of the 
results reported. Most studies adopted a societal perspective and considered a broad 
range of direct medical costs, including those associated with OAB-related 
consequences such as urinary tract infections, skin conditions, falls and fractures. 
Several studies also considered indirect costs resulting from OAB such as productivity 
losses, travel expenses and home services (Ganz et al., 2010; Hu et al., 2003; Inoue et 
al., 2008; Irwin et al., 2009; Klotz et al., 2007; Reeves et al., 2006; Onukwugha et al., 
2009; Sung et al., 2012).  
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Table 2.3:    Annual disease-specific costs for OAB; summary of cost-of-illness studies 
Reference Country(ies) Costs included 
Total annual 
cost 
(cost year) 
Europe    
Irwin et al 
(2009) 
Germany, Italy, 
Spain, Sweden, 
UK, Canada 
Direct: GP consultations; drug 
therapy;  diagnostic procedures; 
pads; OAB-related 
consequences (UTI, fractures, 
skin infections, depression); 
nursing home admissions 
Indirect: productivity loss 
€9.7 billion 
(2005) 
Klotz et al 
2007  
Germany Direct: physician visits; 
diagnostic procedures; specialist 
care; nursing home care; 
physiotherapy; drug therapy; 
medical aids/devices; OAB-
related consequences (UTI, skin 
infections, depression, falls, 
fractures) 
€4.0 billion 
(not stated) 
Reeves et al 
2006 
Germany, Italy, 
Spain, Sweden, 
UK 
Direct: physician visits; drug 
therapy, pads; OAB-related 
consequences (UTI, skin 
conditions, falls, fractures) 
€4.2 billion 
(2000) 
North 
America 
   
Ganz et al 
2010 
United States Direct: primary care; specialist 
care; diagnostic procedures; 
drug therapy; surgery; physical 
therapy; emergency 
department; pads; pantiliners; 
diapers; latex gloves; bedside 
toilets; skin protection; OAB-
related consequences (UTI, falls, 
fractures, depression, nursing 
home admission) 
Indirect: productivity loss 
$US65.9 
billion 
(2007) 
Hu et al  2003 United States Direct: diagnostic; physician; 
surgery; drug therapy; home 
care; routine care; OAB-related 
consequences (UTI, falls, 
fractures, skin conditions, 
nursing home admission, 
$US12.0 
billion 
(2000) 
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hospital stays) 
Indirect: productivity loss 
Onukwugha 
et al 2009 
United States Direct: outpatient; inpatient 
services; drug therapy; pads; 
OAB-related consequences (UTI, 
falls, fractures, skin infections) 
Indirect: productivity loss 
$US24.9 
billion 
(2007) 
Asia    
Inoue et al 
2008 
Japan Direct: physician visits; hospital 
admission; drug therapy; 
surgery; behavioural therapy; 
travel; OAB-related 
consequences (UTI, falls, 
fractures, skin infections) 
Indirect: productivity loss 
¥956.2 billion 
(not stated) 
Sung  et al 
2012 
South Korea Direct: physician visits; drug 
therapy; diagnostic costs; pads; 
diapers; cleaning 
Indirect: productivity loss 
KRW117.5 
billion 
(2006) 
 
Abbreviations: GP, general practitioner; KRW, Korean Won; UTI, urinary tract infection. 
 
Although the methodologies and assumptions used in each of the studies differed, the 
annual cost-of-illness estimates suggest that the economic burden of OAB is 
considerable.  
2.5   Current Treatment   Options 
OAB is typically treated in a stepwise manner, following a pathway beginning with 
conservative measures and moving through pharmacological treatment to 
invasive/surgical interventions. Conservative measures include lifestyle and 
behavioural modifications, such as reducing caffeine intake, optimising fluid intake, 
and weight loss. Some patients may benefit from bladder training, which can be 
combined with pelvic floor exercises. 
 
Oral pharmacotherapies, antimuscarinic agents and the β3-adrenoceptor agonist 
Mirabegron represent an alternative option either alone or in combination with 
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lifestyle and behavioural changes for those in whom these measures do not produce a 
satisfactory response. Minimally invasive treatments, including botulinum toxin-A 
(BoNT-A) injection, are generally used for patients refractory to oral 
pharmacotherapies (Abrams et al., 2013; Gromley et al., 2015; Lucas et al.,2015). 
2.6   Treatment Guidelines 
Several international urology bodies and national urology/clinical bodies have 
developed clinical practice guidelines for the management of OAB. All of the clinical 
guidelines follow a stepwise management approach, and treatment strategies are 
similar for men and women (Abrams et al., 2013; Gormley et al., 2015; Lucas et al., 
2015).  
 
Generally, clinicians should offer patient education and recommend lifestyle 
modification with behavioural and physical therapy following initial assessment. Of 
note, the International Consultation on Incontinence (ICI) and American Urological 
Association/Society for Urodynamics, Female (AUA/SUFU) suggest to consider adding 
oral pharmacotherapy in combination with lifestyle/behavioural treatment (Table 2.5). 
Second-line treatment consists of oral pharmacotherapy if lifestyle/behavioural 
treatment is not successful. The AUA/SUFU guidelines recommend trying a different 
oral therapy if a patient experiences inadequate symptom control and/or 
unacceptable adverse events with the initial oral therapy. The minimally invasive 
surgical techniques of BoNT-A, peripheral tibial nerve stimulation and sacral 
neuromodulation are options for patients who are refractory or intolerant to one or 
two oral therapies. However, patients should first be evaluated by an appropriate 
specialist.  
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Table 2.4:  Summary of the key international guidelines for the management of OAB. 
  Recommendations   
Group 
Last 
updat
e 
(data 
cut-
off) First-line Second-line Third-line Fourth-line 
Mirabegron 
comments 
ICI 2013 
(Dec 
2012) 
Lifestyle advice, 
pelvic floor 
muscle training, 
scheduled 
voiding regimes, 
behavioural 
therapies and 
antimuscarinics 
BoNT-A, 
neuromodulatio
n and bladder 
augmentation  
– – Not currently 
recommended 
(last update 
was prior to 
Mirabegron 
launch; phase II 
and III data 
reviewed in 
text)  
AUA/SUF
A 
2015 
(Feb 
2014) 
Behavioural 
therapies ± 
Mirabegron or an 
antimuscarinic 
Mirabegron or 
an 
antimuscarinic 
BoNT-A, 
peripheral tibial 
nerve 
stimulation or 
sacral 
neuromodulatio
n 
– Included as 
first- or second-
line option. 
EUA 2015 
(April 
2014) 
Individualised 
behavioural and 
physical 
therapies 
including pelvic 
floor muscle 
training 
Mirabegron or 
an 
antimuscarinic 
Peripheral tibial 
nerve 
stimulation 
BoNT-A, 
sacral nerve 
stimulation, 
bladder 
augmentatio
n or urinary 
divertion 
Recommends 
Mirabegron, 
but cautions 
that possible 
long-term side 
effects remain 
uncertain 
 
Most of the national guidelines for OAB management mirror the advice offered by the 
international societies, with some key differences. Notably, the National Institute for 
Health and Clinical Excellence (NICE) provide some specific guidance about which 
antimuscarinic to prescribe (NICE 2013a). NICE also provides separate and specific 
guidelines for the use of Mirabegron (NICE 2013b), where it is recommended as an 
option for treating the symptoms of OAB in patients for whom antimuscarinic drugs 
are contraindicated or clinically ineffective, or who have unacceptable side effects. 
Similarly, Mirabegron is specifically recommended as a first- or second-line option by 
the AUA/SUFA and EAU guidelines (Gormley et al., 2015; Lucas et al., 2015), but the 
latter advises caution that the risk of possible long-term side effects remain uncertain 
(Lucas et al., 2015). 
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2.7   Unmet Need 
Antimuscarinic agents have established efficacy in the treatment of OAB symptoms, 
and reduce the daily number of micturitions, urgency episodes and incontinence 
episodes compared with placebo (Buser et al., 2012; Nabi et al., 2006). However, 
antimuscarinic agents have several limitations which include unwanted adverse events 
and high rates of discontinuation (Oefelein et al., 2011). For many patients, the 
benefits of antimuscarinic agents do not outweigh the drawbacks despite the 
bothersome nature of their symptoms, highlighting a clear unmet need for individuals 
with OAB (Sexton et al., 2011). 
Muscarinic receptors, the target of antimuscarinic agents, are present not only in the 
bladder, but also in other organs including the salivary glands, gastrointestinal tract, 
eyes, heart and brain (Abrams et al., 2006). Systemic blockade of muscarinic receptors 
by antimuscarinic agents leads to several class-related (i.e. anticholinergic) adverse 
events, the most common of which are dry mouth, constipation, headache and blurred 
vision. Although these events are generally mild to moderate in nature, they can affect 
adherence and persistence on therapy.  
 
Antimuscarinic agents also have the potential to cause more serious adverse events 
involving the CNS (Oefelein et al., 2011). These events include somnolence, dizziness, 
depression, cognitive impairment, psychosis, electroencephalogram changes, sleep 
deficits, hallucinations, confusion and behavioural disturbances (O’Mahony et al., 
2015). The elderly, in particular, may be at increased risk of CNS events because of 
anticholinergic load or burden.  
2.8   Adherence and Persistence 
Adherence and persistence are important factors for the effective treatment of OAB, 
as patients may require long-term medication. Adherence (or compliance) is the extent 
to which a patient acts in accordance with the prescribed dose and interval of a dosing 
regimen; it is often expressed as the number of doses prescribed in relation to the 
dispensing period, i.e. the medication possession ratio (MPR). Persistence is the time 
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from initiation of therapy to discontinuation of therapy. Persistence can be reported 
either as a continuous variable, i.e. the number of days for which therapy was available, 
or as a dichotomous variable measured at the end of a predefined time period, i.e. 
proportion of “persistent” or “non-persistent” patients (Wagg et al., 2015).  
By either measure, adherence and persistence with antimuscarinic agents is low. 
Persistence with antimuscarinic agents appears to drop off rapidly after treatment 
initiation, with 43% to 83% of patients discontinuing their medication within the first 
30 days (Sexton et al; 2011).  
Several studies have identified risk factors associated with non-persistence with 
antimuscarinic agents, which have been captured in the systematic review by 
Veenboer & Bosch (2014). These include: 
• Oxybutinin use; 
• Immediate-release formulation use; 
• Age (i.e. lower persistence among younger adults); 
• Gender (i.e. better persistence in women). 
The reasons most commonly given for discontinuing antimuscarinic agents were that 
treatment was not effective or did not work as expected or because of adverse events 
(Krhut et al., 2014; Schabert et al., 2009; Benner et al., 2010; Campbell et al., 2008; 
Dmochowski et al., 2007).  
Long-term persistence rates with OAB medications are lower than those observed with 
medications used for other common chronic conditions according to a retrospective 
analysis of US prescription claims. After 6 months, persistence rates were 47% for 
intraocular prostaglandin analogs, 56% for statins, 56% for bisphosphonates, 66% for 
oral antidiabetics, 63% for angiotensin II receptor blockers, and 28% for OAB 
medications. At 1 year, these rates decreased to 32%, 43%, 41%, 54%, 50%, and 18%, 
respectively (Yeaw et al., 2009).   
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There is both a humanistic and economic cost of discontinuing antimuscarinic agents. 
Even if therapy has been successful, symptoms relapse rapidly and HRQoL scores 
deteriorate within 1 month of discontinuing treatment (Lee et al., 2011b).  
2.9   Mirabegron 
Mirabegron has received Marketing Authorization in Europe, North America, Asia, and 
Australia (Astellas Pharma Australia Pty Ltd 2016; Astellas Pharma Europe B.V. 2012; 
Astellas Pharma US 2012; Astellas Pharma Inc. 2011; Astellas Pharma Canada Inc 2015).  
Mirabegron offers the first new class of treatment for OAB in over 30 years and a 
different mechanism of action to the antimuscarinics (Chapple et al., 2014). 
Mirabegron is indicated in adults with OAB for treatment of symptoms of urgency, 
increased micturition frequency and/or urgency incontinence (Astellas Pharma Europe 
B.V. 2012; Astellas Pharma US 2012; Astellas Pharma Inc. 2011; Astellas Pharma 
Canada Inc 2015). 
 
2.10  Chapter  Summary  
This chapter provided a good overview of OAB. The ICS definition of OAB is now widely 
applied and accepted. The prevalence of OAB is estimated to increase to 546 million 
world-wide by 2018, representing an increase of around 20%. OAB symptoms have a 
profound impact on HRQoL as measured by both disease-specific and generic PRO 
measures and also impact productivity (employment status) when compared to 
matched controls or those with no or minimal symptoms. Thus the economic burden 
of OAB is considerable. Current treatment options and clinical guidelines put oral 
pharmacotherapies as second line if lifestyle and behavioural treatment is not 
successful. Antimuscarinic agents have been the mainstay pharmacological treatment 
for the past 30 years, but the recent launch of Mirabegron which has a different 
mechanism of action and not associated with antimuscarinc related side-effects 
presents a different option. Long term persistence rates with OAB medications are 
lower than those observed with medications used for other common chronic 
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conditions. There are humanistic and economic costs of discontinuing antimuscarinc 
agents. 
The next chapter will focus on the impact on HRQoL of treatment of OAB, as measured 
by generic and disease-specific instruments.  
 
Chapter 3:   Assessing Patient Reported Outcomes in OAB 
 
3.1   Introduction 
 
Chapter 2 provided the background to OAB as a disease, including current treatment 
options, unmet need and the introduction of Mirabegron as the latest addition to the 
armamentarium available to clinicians in the treatment of OAB. As OAB is a symptom 
based condition the significant impact on a patient health-related quality of life 
(HRQoL) was also discussed. This chapter will continue with discussion on the impact 
on quality of life and their measurement through use of patient reported outcomes 
(PROs) in OAB. 
3.2   Patient Reported Outcomes (PROs) in OAB 
OAB is a disease prevalent condition which has a profound impact on health-related 
quality of life (HRQoL) (Coyne et al., 2008). The efficacy of OAB treatments has been 
traditionally assessed using 3-7 day bladder diaries capturing information on objective 
end-points such as micturition frequency and number of incontinence episodes 
(Benner et al., 2010). However, data pertaining to the clinical significance of these end-
points have only recently been seen in the literature (Thomas et al., 2014). As these 
objective measures do not capture the patient perception of treatment or quality of 
life, inclusion within clinical trials of validated PROs allow both objective and subjective 
endpoints to be captured. This generates important insights in to the performance of 
treatments that can subsequently be shared with regulatory bodies, Payers and for 
clinical decision making. Subjective outcomes provide essential information on the 
impact of bothersome side effects as these can impact persistence and adherence 
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(Benner et al., 2010; Khullar et al., 2013). Furthermore, subjective outcomes enable for 
an understanding of patient expectations which can also influence the impact of OAB 
on HRQoL (Khullar et al., 2013). In this chapter the strengths, limitations and insights in 
to the impact on HRQoL of treatment for OAB will be discussed using the three PRO-
related publications submitted as part of this thesis. The research includes both 
disease specific and generic PRO measures.  
 
3.3   Patient-Reported Outcomes with the ß3-Adrenoceptor Agonist Mirabegron in a 
Phase 3 Trial in Patients with Overactive Bladder. 
http://onlinelibrary.wiley.com/doi/10.1002/nau.22844/full 
This paper includes pre-specified analyses and post-hoc analysis of the pivotal phase 3 
study (SCORPIO:NCT00689104) in which 1,987 patients were randomised to placebo, 
Mirabegron 50 or 100mg/day or Tolterodine extended release (ER) 4mg/day  as an 
active control. Although the incidence of  overall treatment emergent adverse events 
were similar in all arms, the incidence of dry mouth with Tolterodine ER 4mg was 
10.1% and Mirabegron 50mg/day was 2.8%. It is reasonable therefore to hypothesise 
that the improvements in the balance between efficacy and tolerability may translate 
in to HRQoL improvements. The PROs used in this study included Treatment 
Satisfaction-Visual Analogue Scale (TS-VAS), OAB questionnaire (OAB-q), Patient 
Perception of Bladder Condition (PPBC) and work productivity and activity impairment: 
specific health problem (WPAI-SHP) instrument. Incontinent pad use was also 
monitored to evaluate the effect of therapy on OAB-related medical care resources. Of 
these, PROs TS-VAS, Symptom Bother component of the OAB-q and PPBC showed 
significant improvement with Mirabegron 50 and 10mg versus placebo and is reported 
in the pivotal trial 85. Data for other PROs (secondary endpoints) were reported in this 
trial including a post-hoc analysis in the subgroup of patients with incontinence at 
baseline. 
The results showed significant improvements with 12 weeks of therapy with 
Mirabegron at the approved dose compared to placebo in OAB-q components and 
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PPBC. These improvements were not seen with Tolterodine 4mg ER compared to 
placebo.  Numerical improvements were also seen with Mirabegron with respect to 
WPAI-SHP scores and with at least numerical reductions in incontinence pad use at 4 
weeks. With regards to whether or not these differences were clinically meaningful 
with WPAI-SHP, it was not possible to ascertain as minimal clinically important 
differences do not appear to have been established.  The lack of significant differences 
in pad use at 12 weeks may also be due to patients even when continent using them as 
reassurance, a high placebo response, and a lack of drug effect or other types of 
incontinence. The differences seen in the incontinent group were even greater than 
that seen in the overall population, suggesting that patients with incontinence 
perceive the benefits of Mirabegron to be greater than those who do not have 
incontinence. This was despite the fact the placebo effect was also greater in this 
subgroup. These findings also support the efficacy of Mirabegron in terms of urinary 
frequency, urgency and urgency incontinence reported in this trial and the PRO 
analyses in the pooled phase 3 trials reported previously (Khullar et al., 2013; Hershorn 
et al., 2013). They also support the findings from the generic EuroQol  questionnaire 
(EQ-5D) analysis which reported significant  changes from baseline  for EuroQol five 
dimensions questionnaire utilities for Mirabegron 50mg/day versus Tolterodine ER 
4mg/day. This paper will be discussed in more depth in the next section.  
The limitations of this analysis lie in the 12 week duration of the study which is typical 
for registration trials in OAB.  It is therefore difficult to assess the long term impact 
Mirabegron may have on HRQoL. The study design was also not powered to compare 
Mirabegron head-to-head with Tolterodine 4mg ER which in the real-world setting 
would be a key comparator. In addition, consistent with the primary efficacy analysis 
(Hershorn et al., 2013; Nitti et al., 2013) there is a large placebo effect which may to 
some extent obscure treatment effects. 
3.4   Paper 2: Understanding the effects on HR-QoL of treatment for overactive 
bladder: a detailed analysis of EQ-5D clinical data for Mirabegron. 
http://www.tandfonline.com/doi/full/10.3111/13696998.2013.802240 
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For the purposes of cost-effectiveness analyses, especially where the requirement is to 
provide an estimate of the Quality Adjusted Life years (QALYs) it has become 
increasingly important to include generic PRO measures in clinical trials. The EuroQoL 
five dimensions questionnaire (EQ-5D) is one of the most widely used for this purpose 
and in fact preferred by some prominent HTA bodies such as NICE (NICE, 2008).  
Traditionally, EQ-5D data collected in clinical trials is focussed on utility-weighted EQ-
5D profiles required to estimate QALYs. However, this is a rich dataset comprising of 
both patients self-reported health on the EQ-5D dimensions as well as patients overall 
assessment of their health on a visual-analogue scale ( the EQ-VAS), therefore apart 
from estimating utility gains it may also provide further insights in to the underlying 
changes in HRQoL. Simply collapsing the EQ-5D health profile data in to a single value 
by means of weighting may result in loss of additional information and introduce 
exogenous variation that can bias statistical inference (Parkin et al., 2010). Also, 
analysis of EQ-VAS provides useful insights in to the patient perspective given that 
there are differences between public preferences and those of patients.  Thus the aims 
of this paper were to demonstrate the insights possible from a range of statistical 
analyses of the EQ-5D data.  
The overall objectives were to estimate the changes in utility with Mirabegron using 
pooled EQ-5D data collected from three large scale multicentre  phase 3 trials 
completed in Australia and Europe (178-CL-046, NCT00689104);USA and Canada (178-
CL-047, NCT06612909); and US, Canada and Europe(178-CL-074, NCT00912964). 
Additional objectives were to investigate changes in EQ-5D profiles that drive the 
changes in utility and if these changes are consistent with the patient’s own views of 
their health on the EQ-VAS. This analysis also reported comparisons of each patient’s 
EQ-5D profiles between each study time point and baseline evaluation using the 
Paretian Classification of Health Change (PCHC) as defined by Devlin et al (2010). 
Finally in order to investigate the idea that some treatments may be faster acting than 
others even if there is no difference in outcomes at 12 weeks, a comparison of the  
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Areas Under the Curve (AUC) of changes from baseline in UK utility scores 4, 8 and 12 
weeks was performed. 
The results showed Mirabegron to be effective on the EQ-VAS and the EQ index .The 
EQ-VAS was the most consistent in showing superior outcomes with Mirabegron, 
especially when compared to Tolterodine with the Mirabegron 100mg dose also 
showing superiority when compared to placebo. On the EQ index however, 
Mirabegron 50mg showed statistically significant improvement compared to 
Tolterodine at 12 weeks in the modified intention-to-treat analysis (Mod-ITT), but it 
did not do so for the 25mg and 100mg dose and over placebo. The changes seen in the 
EQ-5D utility index, although small are consistent with other studies which used EQ-5D 
in OAB patients.  The analysis showed Mirabegron to have a consistently stronger 
effect on the EQ-VAS which raises the questions about the ability of the EQ-index 
(descriptive system) to reflect aspects of HRQoL relevant to OAB. The descriptive 
system at the time had only three levels of severity which may make it less sensitive to 
smaller variations in effectiveness. This is especially relevant in OAB where patients 
generally score in 1or 2 in most dimensions as they do not have severe health 
problems. In this study there was also a high ceiling effect (11111- no problems on any 
EQ-5D dimensions) at baseline, although this was similar across all arms. A re-analysis 
that excluded these patients at baseline (11111) showed statistically significant results 
between groups were maintained, although effect size of between group differences 
increased. It should also be remembered that EQ-Index values represent the general 
public whereas the EQ-VAS captures the patients’ overall assessment of their health.  
Another interesting finding was the rapid effect of Mirabegron 50mg at 4 weeks shown 
in EQ-VAS and EQ-index when compared to Tolterodine. This may be explained by the 
higher incidence of bothersome anti-muscarinic side effects for example, dry mouth 
seen with Tolterodine. Focussing solely on differences at 12 weeks may not adequately 
represent these gains, which is why the AUC analyses is a very good representation of 
the significant gains seen with Mirabegron 50mg compared to placebo and Tolterodine 
(using change from baseline in the VAS). On the other hand, the new method (the 
PCHC approach) did not show any advantages with Mirabegron at any dose. This new 
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approach would allow departure from the utility weights and allow more exploitation 
of the responses to the descriptive system but again it may not have detected the 
changes between treatment and control groups due to the limitations of the EQ-5D in 
detecting quality of life impacts in OAB mentioned earlier. The question as to how 
adverse events may impact the EQ-Index or EQ-VAS was also asked and analysis 
performed in which the incidence of most relevant side-effects in all groups was 
assessed and then the impact on EQ-Index and EQ-VAS. Although a higher incidence of 
dry mouth at any time point was noticed with Tolterodine, this did not translate in to 
any significant changes in EQ-index or EQ-VAS scores.  
There are several limitations of this study. These pivotal phase 3 studies were designed 
to assess efficacy of Mirabegron and not specifically to assess improvements in quality 
of life as measured by EQ-5D. The analysis excluded patients who did not have EQ-5D 
data available at 12 weeks and those with major protocol deviations to allow for a 
much clearer understanding of mirabegron’s impact on a patient’s HRQoL as measured 
by EQ-5D. However, when the analysis was repeated with inclusion of patients who 
took at least one dose of study drug, similar results were seen with the EQ-VAS  with 
Mirabegron (all doses) showing significantly better results than Tolterodine at 12 
weeks  with two of them better then placebo. However, results were similar for the 
EQ-5D index but not statistically significant. The inclusion of those patients with 
protocol deviations and last observation carried forward approach may have had a 
‘watering down’ effect. Finally, the EQ-5D data in these pivotal studies came from 
patients in Europe, US, Canada and Australia, yet the UK EQ-5D value sets were used 
which may have an impact on the results.  
3.5 Paper 3: Estimating EQ-5D and OAB-5D health state utilities for patients with 
overactive bladder. 
www.hqlo.com/content/11/1/200 
 
Despite the analysis discussed in the previous section, utility data in OAB is still lacking. 
EQ-5D has a number of limitations especially in terms of sensitivity in specific disease 
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contexts (Stolk et al., 2003; Eurich et al., 2006). In the previous section the limitations 
of EQ-5D instrument were discussed in the context of measuring impact on quality of 
life for treatment in OAB. The analysis pointed to a lack of sensitivity of the EQ-5D 
instrument with respect to subtle changes in OAB symptomology. Desroziers et al 
(2013), therefore explores this concept further by deriving utility values from a 
disease-specific instrument such as the OAB-q. 
To overcome the limitations of the EQ-5D, Yang et al (2009), developed a 5-
dimensional preference based disease-specific measure, named OAB-5D which was 
derived from the overactive bladder questionnaire (OABq)(Yang et al., 2009; Young et 
al., 2009). Even though OAB-q was not originally designed to generate utility values, 
using the Time Trade-off method (TTO) and UK general population survey, Yang et al 
(2009) built a model to derive utilities from the 5 items forming the OAB-5D. The 
objective of the analysis in this paper was to estimate utility values in patients with 
OAB using data from the three pooled clinical trials for Mirabegron and using the 
generic and disease specific instruments (EQ-5D and OAB-5D respectively). In addition, 
this analysis investigates the relationship between utilities and symptoms and 
evaluates the sensitivity to changes in OAB symptoms of both preference based 
instruments.  
In the clinical trials patients had to complete a 3-day bladder diary before each 
scheduled visit. The main end-points derived from the diary were mean number of 
micturition episodes per 24 hours, mean number of frequency episodes per 24 hours, 
mean number of urgency episodes (grade 3 and 4) per 24 hours and mean volume 
voided per micturition. For micturitions and incontinence episodes 5 severity levels 
were defined based on the distribution (quintiles) of events observed in the pooled 
trials. To value the OAB health states, Yang et al (2009) chose five items from the OAB-
q to construct the new health state classification system (OAB-5D). These consisted of: 
urge to urinate, urine loss, sleep impact, coping strategy, and concern with OAB, where 
each dimension has five levels of severity with level 1 denoting no problem and level 5 
indicating extreme problem (Yang et al., 2009). This resulted in a total of 3125 health 
states that can be defined using the OAB-5D classification system (versus 243 from the 
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EQ-5D system). Therefore all OAB-q data which contain these five items can be 
mapped to a specific OAB-5D health state. 
In terms of the statistical analysis utility scores from EQ-5D and OAB-5D were 
described as means and standard deviations and then estimated by symptom severity. 
For each symptom (micturition and incontinence) a liner regression model was used to 
estimate utility by symptom level (1-5) adjusting for age, gender, study and 
geographical region. Differences between OAB-5D and EQ-5D utilities were also 
estimated by symptom level using similar methods. Finally, as a test of sensitivity of 
the instruments, utility changes from baseline to 12 weeks were tested according to 
response in symptoms, defined as 3possible items: ‘improvement higher than 1 level 
of symptoms’, ‘stable’, or ‘worsening higher than 1 level of symptoms’. 
The results showed that the mean EQ-5D and OAB-5D utility decreased with symptom 
severity (i.e. from level 1 to 5) with OAB-5D showing a slighter larger change than EQ-
5D (0.1 versus 0.07 respectively). After making adjustments using linear regression 
modelling the differences at the higher severity levels for micturitions and 
incontinence episodes (levels 4 and 5) were not significant between OAB-5D and EQ-
5D. However, at the milder end of the spectrum (levels 1 and 2) a significant difference 
was observed in utility values between OAB-5D and EQ-5D.  
The estimated regression coefficients confirmed that utilities decreased with symptom 
severity after adjusting for patient characteristics. Micturitions and incontinence has a 
similar impact on EQ-5D utilities, but micturitions seemed to have a greater impact on 
OAB-5D utilities than incontinence. For example, at equal micturition symptoms, an 
improvement in incontinence level from level 5 to 1 (> 3 incontinence episodes per day 
to 0) was associated with an increase in EQ-5D utility of 0.052 (p < 0.0001) and 0.076 in 
OAB-5D utility (p < 0.0001).  
In terms of responsiveness of HRQoL and clinical symptoms, the mean changes from 
baseline in utility were positive in all groups of patients (improving, stable and 
worsening) and were greater in responders than in non-responders. There were no 
significant changes from baseline utility between worsening response and stable 
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response with EQ-5D but differences were significant with OAB-5D. In patients with 
mild micturition frequency and incontinence episodes, there was again no significant 
change in utility with EQ-5D between improvement and stable response. However, 
with OAB-5D differences in utility were significant. However, in severe cases 
differences in utility were significant for both EQ-5D and OAB-5D between 
improvement and stable response. No significant differences were observed between 
worsening response and stable response in severe cases for both preference based 
instruments. 
Finally, overall changes in utility from baseline were greater with OAB-5D when 
compared to EQ-5D for all symptoms, in both improving and stable patients. Although 
both OAB-5D and EQ-5D demonstrated that utility scores increased as symptoms 
improved, OAB-5D had a greater range of variation according to symptom severity. 
Incremental utilities at different symptom levels were also different between OAB-5D 
and EQ-5D which is surprising considering both instruments are expected to provide 
value on the same scale (0 to 1) and use the TTO method. The correlation between 
OAB-5D and EQ-5D in the general population was moderate (r = 0.34: p < 0.0001) 
which maybe be explained by the larger standard deviation in the EQ-5D utilities 
reflecting natural variation in health status not related to OAB. 
It must also be noted that the equation used for EQ-5D had low predictive power, 
which means that a much larger number of patients would be required to detect 
changes in utility between different groups of patients. Another limitation of the 
regression models used was that they do not capture the effect of potential non-
urology related dimensions. Measuring the impact of adverse events using trial data is 
also difficult since the periods when patients experience these events rarely coincide 
with the assessment dates. The OAB-5D instrument does not have a dimension to 
detect the impact of adverse events, whereas the EQ-5D instrument as generic 
measure is expected to capture deteriorations in HRQoL related to adverse events.  
Another important finding in this analysis was to learn that micturition frequency does 
affect the utility score even when adjusting for incontinence episodes. The interaction 
between micturition frequency and incontinence episodes using the liner regression 
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models (p = 0.1283) was found not be significant suggesting that micturition frequency 
and incontinence episodes impact utility independently of each other and therefore 
the effects of the different symptoms are additive.  
Finally, this study demonstrated the greater responsiveness of the OAB-5D instrument 
in patients with mild OAB compared to EQ-5D. However, using EQ-5D to measure 
utilities does have the advantage to compare the values across other conditions and it 
can capture the impact of adverse events. However, larger sample sizes may be 
required to detect differences between treatments or patient groups. In conclusion, 
therefore both sets of utilities can be used for cost-effectiveness modelling although 
they will lead to different incremental cost-effectiveness ratios.  
3.6   Chapter Summary 
The patient reported outcomes included in the pivotal studies for Mirabegron 
demonstrate significant improvement with 12 weeks of therapy (OAB-q and PPBC). The 
differences seen in the incontinent sub-group were greater than the overall population. 
However, the studies are of 12 week duration, therefore difficult to assess the long-
term impact on HRQoL.  Tolterodine was an active control in only one of the studies 
and all three studies were focussed on efficacy, therefore not powered to detect 
differences in quality of life. 
The pooled analysis of EQ-5D demonstrated Mirabegron to be effective on both the EQ 
index and EQ-VAS, but only showed statistical significance versus Tolterodine on the 
modified intention-to-treat analysis. A high ceiling effect (11111) was observed at 
baseline although when excluded statistically significant results between groups were 
maintained. Deriving utility values from a disease-specific instrument using an 
established mapping algorithm is one way to counter the lack of sensitivity seen in the 
generic EQ-5D questionnaire. This analysis showed a greater responsiveness of the 
OAB-5D instrument in patients with mild OAB compared to EQ-5D. However, using EQ-
5D to measure utilities does have the advantage to compare the values across other 
conditions and it can capture the impact of adverse events. Both sets of utilities can be 
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used for cost-effectiveness modelling although they will lead to different incremental 
cost-effectiveness ratios. 
In this chapter the impact of Mirabegron on HRQoL was presented using three 
published papers. The next chapter is focussed on how Mirabegron compares to other 
pharmacological treatments in terms of efficacy and safety.  
 
Chapter 4:  Comparing Efficacy and Safety of Mirabegron with Antimuscarinics 
4.1   Introduction 
In the previous chapter the PROs specifically within the context of OAB and treatment 
with Mirabegron were discussed. These analyses are based on the pivotal studies for 
Mirabegron which are predominantly placebo controlled trials with only one of them 
including Tolterodine but only as an active control. However, HTA, treatment 
guidelines and reimbursement policies requires comparison of all competing 
interventions. The ideal scenario would be to have well designed and conducted RCTs 
that simultaneously compare all competing interventions. Pivotal trials aiming to 
obtain regulatory approval often compare with placebo or standard of care as there is 
no commercial incentive to compare the new treatment with active control treatment.  
Also, interventions of interest may vary by country and change over time due to new 
evidence and insights. Therefore, in the absence of direct comparisons between 
treatments of interest an indirect treatment comparison can provide useful evidence 
to estimate differences in treatment effects between competing interventions. There 
is now an increasing acceptance of Network Meta-analysis (NMA) by HTA bodies such 
as CADTH (Canada), NICE (UK), SMC (Scotland), IQWiG (Germany) and HAS (France) 
and they form a key part of healthcare decision-making (Laws et al., 2014). A recent 
study reviewed NMA guidelines from 33 countries: of these 9 countries had very 
detailed recommendations on the conduct of NMA (UK, Australia, Belgium, France, 
Spain, Germany, Scotland, South Africa and Canada) (Laws et al., 2014). It is possible to 
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perform one NMA for submission to multiple HTA and reimbursement bodies (Lumley 
et al., 2002). 
The aim of the Maman et al (2014) is therefore to compare the clinical efficacy and 
safety of the most widely used OAB treatments and more specifically to estimate the 
efficacy and safety of Mirabegron compared with antimuscarinics. This NMA was also 
submitted as part of a NICE single technology appraisal assessment of Mirabegron in 
2012. 
 
4.2   Comparative Efficacy and Safety of Medical Treatments for the Management of 
Overactive Bladder: A Systematic Literature Review and Mixed Treatment 
Comparison. 
http://dx.doi.org/10.1016/j.eururo.2013.11.010 
 
This review considered all RCTs studying the efficacy or the safety of pharmacologic 
treatments in the management of OAB and also considered studies on most approved 
drugs used in Europe for the management of OAB.  
A Bayesian Mixed Treatment Comparison (MTC) was conducted to estimate relative 
efficacy and safety of Mirabegron compared to all OAB treatments.  The MTC (or NMA) 
is essentially an extension of a meta-analysis Lumley (2002).  The main advantage of 
conducting a MTC compared to a meta-analysis is that the estimation of the relative 
effect between two treatments uses all the information available from the network of 
evidence available including both direct and indirect evidence. 
This MTC was conducted in both the general OAB population and the subgroup of 
patients incontinent at baseline. The parameters included in the analysis were 
micturition frequency, incontinence and urge urinary incontinence (UUI) per 24 hours. 
Eligibility criteria, for a study to be included was that it had to have reported changes 
in these efficacy symptoms over 8-16 weeks (reported changes over 12 weeks were 
retained). Studies reporting safety outcomes if number of patients reporting dry 
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mouth, constipation, and/or blurred vision over 4-16 weeks could be derived from 
publications. 
Overall, after applying the inclusion/exclusion criteria 44 studies were included in the 
MTC, enrolling 27,309 patients.  Most of the studies were conducted in North America 
or Europe from 2000 to 2013. Over 70% of the studies were placebo controlled. In 
total, there were 129 treatment arms included in the MTC. Fixed effect models were 
used for most outcomes with the exception of dry mouth for which random-effect 
model was used due to heterogeneity between studies. The probability of each 
treatment being more effective then Mirabegron was calculated for different 
superiority margins.  
In terms of the efficacy outcomes, for micturitions (26 studies, 22,040 patients) 
demonstrated that the effect of Mirabegron 50mg did not differ significantly from 
other treatments, except solifenacin 10mg which is more effective. For incontinence 
episodes (17 studies, 13,101 patients) the MTC demonstrated that Mirabegron did not 
differ significantly from the other treatments in terms of reduction of incontinence 
episodes and was statistically superior to placebo. However, solifenacin 5mg had a 
probability of 97% of being superior to Mirabegron and solifenacin 10mg had an equal 
probability. With respect to UUI (18 studies, 16,044 patients) again the Mirabegron 
demonstrated similar results to other antimuscarinics except for solifenacin 10mg 
which was significantly more efficacious.  
In terms of the safety outcomes, in particular dry mouth (44 studies, 27,309 patients), 
Mirabegron 50mg had an incidence of dry mouth similar to placebo (OR: 1.344; 95%Crl 
0.863-2.004). Not surprisingly all antimuscarinics were associated with a higher risk of 
dry mouth compared with Mirabegron 50mg.  Similarly, the incidence of constipation 
associated with Mirabegron was similar to placebo. Blurred vision was relatively rare 
and no significant differences in risk of developing blurred vision were found between 
treatments. 
Results from this MTC suggest that Mirabegron 50mg is similar to antimuscarinics in 
terms of efficacy (micturition frequency, incontinence, UUI) except for solifenacin 
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10mg (UUI and micturition frequency). However, solfenacin 10mg and fesoterodine 
8mg were among the treatments with the highest adverse events, especially dry 
mouth. The drug with the most favourable tolerability profile was Mirabegron 50mg 
with an incidence of dry mouth and constipation comparable to placebo and 
significantly lower than the antimuscarinics.  
This analysis adds on the previous literature reviews and meta-analysis conducted by 
Chapple et al, 2008, which showed that antimuscarinics are more efficacious than 
placebo (Chapple et al., 2008) by firstly including a new treatment (Mirabegron 50mg), 
secondly it included twenty more studies since 2007 and finally with the MTC approach 
it uses both head-to head comparisons as well as comparisons versus placebo.  
One criticism of our MTC could be on the safety outcomes. The MTC considered only 
the adverse events associated with antimuscarinics such as dry mouth, constipation 
and blurred vision, yet ignored adverse events associated with Mirabegron. The pivotal 
studies for Mirabegron 50mg reported hypertension (7.5%), nasopharyngitis (3.9%), 
headache (3.4%), and UTIs (2.9%) (Nitti et al., 2013). The proportions of patients 
experiencing these adverse events however, were not significantly different from 
placebo arms based on pooled analysis except for nasopharyngitis. An MTC analysis 
could not be conducted on this adverse event because this event is not reported in the 
publications on antimuscarinics. 
The efficacy outcomes included in the MTC did not include urgency symptoms which 
could also be seen as a potential weakness given that this forms part of the ICS 
definition for OAB. While this is an important symptom, the measurement of this 
symptom is very subjective and several instruments have been used to try and 
measure urgency, making it difficult to make any credible comparisons.  The volume 
voided per micturition was also not included as this is seen as more of a surrogate end-
point and of less clinical relevance. Other outcomes such as dry rate or resolution of 
incontinence, mean change in day and night time micturitions, urgency driven 
micturitions are relevant but not as frequently reported and therefore not considered 
in the MTC. 
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There were a few sources of heterogeneity with our MTC, namely between studies and 
the variability in follow-up periods between trials. The between study heterogeneity 
could arise from the differences in baseline characteristics of patients in different 
studies e.g. OAB severity at baseline, proportion of previously treated patients etc. 
Fesoterodine studies had more severe OAB at baseline (two studies had more than six 
urgency episodes per day at baseline) therefore with more potential for improvement. 
The FACT-2 placebo controlled trial comparing fesoterodine 8mg and Tolterodine ER 
4mg included approximately 30% previously treated patients, whereas a placebo –
controlled trial of Tolterodine reported efficacy results in a population with 70% 
previously treated patients.  
The other source of heterogeneity was the follow-up periods between trials (from 8-16 
weeks for efficacy and 4-16 weeks for safety outcomes). However, over 72% of the 
trials had a 12-week follow up period and we verified that relative effects at 8 weeks 
and 12 weeks or 12 and 16 weeks were similar when results at both times were 
reported., therefore in the end this was not a major concern. 
One way to account for the heterogeneity is to use random-effect models which 
assumes that every RCT measures the same effect with a degree of variation, therefore 
the CrL around the treatment effect estimated from the MTC accounts for variability 
between studies. The presence of heterogeneity will lead to wide CrL. The fact the CrLs 
do not overlap between two treatments despite the heterogeneity indicates that 
estimated difference in treatment effects between two treatments exceeds the 
difference potentially due to heterogeneity. The fixed-effect model was selected for all 
outcomes except dry mouth suggesting that for this outcome the heterogeneity 
between studies affected the estimation of differences between treatments in the 
probability of dry mouth. However, the reported CrLs around the ORs for dry mouth 
account for this heterogeneity. We can therefore conclude the probability of dry 
mouth with Mirabegron is significantly lower compared to antimuscarinics despite the 
presence of heterogeneity between studies. 
Another way to balance the baseline characteristics and account for heterogeneity 
would be to use meta-regression techniques to adjust for bias associated with effect-
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modifying covariates (Dias et al., 2013a). This would only be feasible however, if these 
variables that drive heterogeneity such as OAB severity and treatment experience are 
systematically reported in publications. It would therefore significantly reduce the 
number of publications included in the MTC.  
Finally, another limitation of this analysis maybe that we only included studies after 
2000. The main reason for this was to ensure greater homogeneity between study 
populations because prior to 2000 more patients were treatment naïve (only 
oxybutynin IR available) and the current definition of OAB was introduced in 2001. This 
did mean that there were fewer studies including oxybutynin IR (hence the wider CrLs) 
but a head-to-head trial of oxybutynin IR with Tolterodine ER 4mg in Asian patients did 
demonstrate that Tolterodine ER 4mg was similar in efficacy but better tolerated 
compared to oxybutynin IR (Dias et al., 2013b). 
 
 
4.3    Chapter Summary  
The NMA forms a key piece of evidence, given that HTA, treatment guidelines and 
reimbursement policies require a comparison of all competing interventions. In the 
absence of direct comparisons between the treatments of interest, an indirect 
treatment comparison can provide useful evidence to estimate the differences in 
treatment effects between competing interventions. The results of this analysis 
demonstrated that Mirabegron was similar in efficacy to antimuscarinics but with a 
more favourable tolerability profile. The analysis adds to the previously conducted 
meta-analyses by firstly including Mirabegron, twenty more studies since 2007 and 
finally the whole NMA approach means that it uses both head-to-head and 
comparisons versus placebo. 
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Chapter 5:    Cost-effectiveness Analyses of Treatments in OAB 
5.1   Introduction 
Thus far the thesis has extensively discussed the quality of life impact of OAB 
medications and the comparative efficacy and safety of these interventions. In this 
chapter, the thesis will discuss how some of these findings and other relevant data 
sources are used to develop the cost-effectiveness analyses.  
In previous cost-effectiveness analyses, Markov models have been based on the 
extensively applied model by Kobelt et al (1998). This model consists of five health 
states each representing a differing level of disease severity with an absorbing state for 
drop-outs who are considered to remain off treatment. In chapter 3, it was shown that 
the main symptoms of OAB (urinary incontinence and micturition frequency) had a 
significant impact on utility independently of each other with moderate correlations 
between changes in these symptoms. We have therefore tried to model the 
progression of these symptoms separately. Apart from this principle change in 
approach we paid more attention to the patient pathways after treatment 
discontinuation due to the high rates of switching and treatment discontinuation 
observed with OAB patients and we chose a time horizon that more accurately 
represents the costs and outcomes of managing a chronic condition. 
There are essentially three publications which will be discussed in this model; a trial-
based cost-effectiveness model; a cost-effectiveness model based on the outputs of 
the network meta-analysis discussed in the previous chapter; and a model that 
quantifies the cost and outcomes of different treatment sequences of OAB 
interventions and tailored for a more regional payer archetype. The trial-based model 
and the model using outputs from the network meta-analysis were both submitted to 
NICE in 2012 as part of the single technology appraisal 
5.2   Cost-effectiveness of Mirabegron compared with Tolterodine Extended Release 
for the Treatment of Adults with Overactive Bladder in the United Kingdom.  
https://link.springer.com/article/10.1007%2Fs40261-014-0240- 
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This was the first economic analysis that compared Mirabegron with currently 
available antimuscarinics agents for the treatment of OAB. A Markov model was 
developed to simulate the therapeutic management, course of disease, and the effect 
of complications in hypothetical cohorts of OAB patients over a 5-year period. As 
mentioned previously, the commonly used Kobelt et al (1998) model was limited to a 
1-year time horizon, and did not model treatment pathways after treatment 
discontinuation, an important limitation given the high discontinuation rates with 
antimuscarinics. We therefore captured the impact of treatment discontinuation and 
switching on costs and OAB symptoms, since persistence affects HRQoL, health status 
and health care resource utilisation (Balikrishnan et al., 2006). HRQoL was assumed to 
be dependent on both variations in symptoms over time and the side effects of 
treatment.  
The model simulated changes in symptoms (micturitions and incontinence) for which 
the model was run in parallel at monthly intervals (60 in total). Every month patients 
could remain on treatment  (Mirabegron or Tolterodine as this was based on the phase 
3 SCOPIO study), switch to another treatment with better efficacy  and price similar to 
solifenacin or discontinue (go to no treatment). A small proportion would be eligible 
for botulinum toxin (BTX) after the next line of therapy (not allowed directly after 
Mirabegron or Tolterodine).  
The probabilities of discontinuation and switching were dependent on adverse events. 
Patients with adverse events could stay on treatment, but incurred a disutility. Patients 
who discontinued therapy could naturally improve and thereby transition to a lower 
severity category after 1 month, or could worsen or stay the same. These patients 
could also restart the previous treatment, could move to a new treatment or remain 
off treatment. If patients were successful on BTX it was assumed they would transition 
to the lowest level of severity and remain there until the end of the simulation. The 
model assumed that the probability of improvement was greatest in the first month 
after which it decreased progressively until month three and then assumed to remain 
constant for the remainder of the simulation. 
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Apart from the general OAB population, the model considered several subgroups such 
as those dissatisfied with previous treatment either due to lack of efficacy or side 
effects, treatment naïve, treatment experienced, elderly patients, female and male 
patients and patients incontinent at baseline. 
Another key feature that distinguishes this model from Kobelt et al’s model is the non- 
arbitrary nature of the health states/symptom severity levels. Symptom severity in the 
model was determined using the SCORPIO trial (Khullar et al., 2013). Initial 
distributions of patients with symptom severity (Incontinence and micturition 
frequency) were based on SCORPIO trial base lines and there were five severity levels 
for each symptom. Transition probabilities between symptom level for Mirabegron 
50m and Tolterodine ER 4mg were estimated using multinomial logistic regression 
models. Finally, both deterministic and probabilistic sensitivity analyses were 
conducted. 
The results showed that in the base case Mirabegron 50mg was cost-effective 
compared to Tolterodine ER 4mg at a willingness to pay (WTP) threshold of 
£20,000/QALY and £30,000/QALY. This is generally the threshold applied by UK NICE. 
Both the deterministic and probabilistic sensitivity analysis demonstrated that the 
model was robust. The incremental cost-effectiveness ratios (ICERs) were also 
consistent in the subgroups analysed. 
Key strengths of this model have already been highlighted by counteracting the 
potential limitations of the Kobelt et al model. One of the key strengths of this model 
were that it captured the effects on HRQoL of variations in symptom severity over a 
longer time horizon as well as capturing the impact  beyond treatment discontinuation 
and switching on costs and health outcomes. It therefore more accurately represents 
the clinical management of OAB. Another strength, of this model, is that it also 
analysed cost-effectiveness in key subgroups. 
In contrast, limitations of this model are centred on the lack of real-world evidence or 
persistence data on Mirabegron. In this context the rates of discontinuation other than 
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adverse events were assumed to be similar for Mirabegron and Tolterodine ER 4mg. 
Given the efficacy and safety profile of Mirabegron 50mg, this assumption was quite 
conservative. The NMA (Chapter 4.2) did show that the probability of Mirabegron 
50mg being more effective than Tolterodine ER 4mg in terms of micturition frequency 
and incontinence is 87.4 and 88.3% respectively. Also, there was no information 
available on the number of patients who receive Botulinum toxin (BTX) therapy 
following drug therapy, so we assume only a small number (1%). Again, this was 
conservative given that BTX is a relatively high cost treatment. There was also 
uncertainly around the potential number of specialist visits. However, it was reassuring 
to see that the sensitivity analyses conducted with all of these parameters, showed 
that the ICERs remained relatively stable and below the thresholds. Finally, another 
potential limitation of the model was influenced by the perspective (Payer/HTA) which 
meant that only direct healthcare costs were captured. The main analysis did not 
capture the indirect costs for example, productivity, and work hours lost, that may be 
incurred in OAB especially when considering some of the subgroups within this 
analysis. 
5.3   Cost-effectiveness of Mirabegron Compared with Antimuscarinic Agents for the 
Treatment of Adults with Overactive Bladder in the United Kingdom. 
https://doi.org/10.1016/j.jval.2015.05.011 
 
This model was almost identical to the model discussed in 5.1. The previous model was 
based on the SCORPIO trial and only compared Mirabegron 50mg with Tolterodine ER 
4mg. However, the reality is that in clinical practice there are several antimuscarinics 
that form standard of care. Furthermore, most of these  are also generic therefore it is 
essential that the incremental value of Mirabegron 50mg is also demonstrated 
compared to these pharmacological interventions which are almost all  within the 
antimuscarinic class.  
In the absence of head-to head trials of Mirabegron 50mg versus each antimuscarinic 
agent the Bayesian NMA (Chapter 4.2), was used to estimate the relative efficacy and 
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safety of Mirabegron compared with placebo and all the antimuscarinic agents 
(Tolterodine ER 4mg; Tolterodine IR 4mg; darifenacin 7.5 and 15mg; solifenacin 5 and 
10mg; fesoterodine 4 and 8mg; Oxybutynin ER 10mg and IR 10 or 15mg and trospium 
chloride modified release 60mg). 
Again, baseline symptom severity was taken from SCORPIO as with the previous model, 
with five severity levels and four coefficients capturing the effect of treatment on the 
probability of moving from one severity level to another (regression analysis, including 
other covariates as well such as age, gender, current severity level). The key difference 
in this model was that in order to incorporate the results of the NMA (efficacy and 
safety) a calibration method was used to fit the model to mean changes in symptoms 
at 3 months determined by the results from the NMA for different products. Finally, 
like the previous model the discontinuation rates were disaggregated to reflect those 
patients who discontinued due to adverse events and those that discontinued due to 
other reasons such as lack of efficacy. 
The results were consistent with the previous model. From a UK NHS perspective 
Mirabegron was cost-effective compared with oral antimuscarinics agents commonly 
used for OAB. This was mainly driven by better persistence and improved patient 
quality of life due to lower risk of adverse events. All ICERs were below the 
£20,000/QALY threshold. Deterministic sensitivity analysis showed that the model was 
most sensitive to transition probabilities between symptom severity levels and 
probabilities of discontinuation. However, the probabilistic sensitivity analysis showed 
that the probability of ICERs being below the £20,000/QALY threshold was high. 
Strengths and limitations of this model have already been discussed in 5.1. However, 
specific to this model the calibration techniques used to incorporate the NMA data in 
this model improved the accuracy of the estimates from the economic model and were 
also viewed positively by NICE during the Single Technology Appraisal (STA) for 
Mirabegron.  A potential weakness may be that the model assumes similar efficacy 
between the IR and ER formulations whereas the associated incidence of dry mouth, 
blurred vision and constipation varies. In the NMA data was pooled from studies using 
IR and ER formulations to estimate efficacy and safety. However, we know that the IR 
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formulations are associated with higher incidence of dry mouth and would expect 
decreased persistence therefore ICERs potentially in favour of Mirabegron (depending 
on price).  
 
5.4    Economic evaluation of pharmacological treatments for overactive bladder 
from the perspective of UK National Health Service (NHS). 
http://dx.doi.org/10.3111/13696998.2014.995300 
 
While the previous analyses have evaluated the cost of individual therapies for OAB, 
the cost and consequences of sequences of drugs incorporating recently approved 
agents such as Mirabegron have not been evaluated.  Therefore, the objective of this 
analysis was to quantify the costs and outcomes associated with different sequences 
of oral antimuscarinic agents and ß3adrencoceptor agonist from the perspective of the 
UK NHS.  
The original idea was to develop a simple, interactive tool that can be used to estimate 
the cost of using different sequences of available therapies for OAB. The model 
focussed on the more tangible outcomes such as patients with controlled symptoms 
(e.g. < then 8 micturition’s/24 hours and <2 incontinence episodes/24 hours, zero 
incontinence episodes or dry rates) which would appeal to local decision makers 
where the cost/QALY argumentation is not always relevant or prioritised. With an 
armamentarium of generic options available for a condition often perceived as a ‘life 
style’ condition the focus of local decision makers is usually on the unit cost or price. 
The aim of this analysis was to aid decision-makers to not only consider the medication 
acquisition costs but also to consider other factors such as efficacy, side –effect 
management, medication adherence as well as the sequence of treatments used in the 
treatment pathway.  
By comparing a treatment sequence consisting of low-cost generic treatments with 
one incorporating branded agents such as Mirabegron, the model demonstrates that it 
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is not necessarily more cost-efficient to use generic therapies. In this analysis, a 
sequence consisting of two generic agents and a third –line branded agent was less 
effective than and was associated with costs similar to a sequence consisting of three 
branded agents. This is mainly a result of these drugs having a better efficacy 
tolerability balance in the branded sequence than the standard sequence. These drugs 
are also associated with better persistence rates and therefore overall lower treatment 
costs (Wagg et al., 2012). The sensitivity analysis also showed that the results are 
sensitive to persistence rates. Current UK guidelines however, continue to recommend 
initial antimuscarinic therapy for the patients with OAB (NICE 171). Furthermore, these 
guidelines stipulate that if initial therapy is not effective or not well tolerated another 
drug with the lowest acquisition cost should be offered (Irwin et al., 2009). The outputs 
from this model therefore challenge these guidelines from a cost and outcomes 
perspective. 
In terms of overall strengths of this analysis, the model can be considered 
comprehensive as it includes multiple factors that affect the overall economic burden 
of OAB in addition to the direct cost of the therapy. These additional factors include 
pad use and costs of co-morbidities like depression and UTI’s arising due to lack of 
control of OAB.  However, work-related productivity costs were not included in this 
analysis and inclusion of these may have led to further cost-savings.  
Again, a limitation of this model was the lack of real-world data on persistence rates 
for some of the agents such as Mirabegron and fesoterodine. These rates are currently 
only available in clinical trials, which is not reflective of clinical practice. As Tolterodine 
was either an active control or comparator in these trials we were able to use these 
persistence rates reported in real-world data for Tolterodine. Patients in this model 
were able to switch medication after 30 days. This is in line with treatment guidelines 
which suggest informing patients that they may not experience full benefits of 
treatment until they have taken therapy for 4 weeks (Nicolson et al., 2008). However, 
the guidelines also recommend that patients should be offered a review of therapy 
before 4 weeks if adverse events are intolerable. Our estimates of persistence also 
suggest that a proportion stop before 30 days, therefore using a minimum of 30-day 
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duration of therapy in the model may not reflect clinical practice in a proportion of 
patients. 
Other limitations are associated with the fact that this model did not include data 
related to the impact on HRQoL. As communicated earlier urinary frequency, urgency 
and incontinence have a significant impact on HRQoL with those who are incontinent 
having a worse HRQoL than continent patients (Coyne et al., 2004; Liberman et al., 
2001). Although HRQoL was not included in this model, the assessment included a 
measure combining urinary frequency and incontinence episodes (controlled versus 
uncontrolled) which are determinants of HRQoL. It was also not possible in this 
analysis to determine accurately the efficacy for second or third line treatments, 
therefore first line efficacy data for all treatments was used.  
Overall, this analysis demonstrates that real-world disease management-related costs 
need to be considered when making recommendations on therapy to ensure that 
benefits to patients are maximised and that funds are spent in the most efficient 
manner.  
5.5    Chapter Summary 
The trial-based model and the NMA model advances the modelling approach used in 
OAB, when compared to previous models developed in this area. For example, the 
non-arbitrary nature of the health states and symptom severity was determined using 
one of the phase 3 studies. The models discussed also captured the changes in HRQoL 
over a longer time horizon as well as capturing cost and health outcomes beyond 
treatment discontinuation. The NMA based model used a calibration method to 
incorporate the results from the NMA. Results in both models were consistent and 
demonstrated that Mirabegron was cost-effective compared to antimuscarinics used in 
clinical practice. The ICERs were driven in favour of Mirabegron by better persistence 
and improved patient quality of life. 
The final model in this chapter focusses on different treatment sequences and the 
impact on cost and health outcomes. This model is aimed at local payers as well as 
challenging the current clinical guidelines that favour the use of generic animuscarinics. 
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It separates the unit costs and highlights other disease management-related costs 
often not considered by local payers.  
Chapters 3, 4 and 5 have focussed predominantly on insights gained from the Phase 3 
program for Mirabegron (the PRO analyses, NMA and cost-effectiveness models). 
While the efficacy of Mirabegron has been well established in the RCT setting, chapter 
6 turns the attention to effectiveness using RWE, collected once Mirabegron has been 
launched and is used widely in clinical practice.   
 
Chapter 6:   Assessing the Impact of OAB Treatments using Real World Evidence 
6.1   Introduction 
In the previous chapters the value of OAB medications has been predominantly 
assessed using a combination of randomised controlled trials (RCTs), some real world 
evidence that does not include Mirabegron and other data sources such as national 
cost data  and other published data sources. In this chapter, the value of OAB 
medications will be assessed using real world evidence that includes Mirabegron (post-
launch). Essentially, this is an assessment of effectiveness in the real world setting.  
There are two papers which will be discussed (Paper 8 and 9). The first publication was 
a retrospective database study using a UK primary care database, the CPRD, while the 
second publication is a model based on the retrospective database study. As discussed 
in chapter 1, this type of evidence is now becoming essential, with some authorities for 
negotiating funding of new drugs and price negotiations.  
 
6.2   Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in 
Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical 
Practice. 
http://dx.doi.org/10.1016/j.eururo.2017.01.037 
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This was a retrospective, longitudinal, observational study of anonymised data from 
the United Kingdom (UK) Clinical Practice Research Data link database (CPRD). Eligible 
patients were aged ≥18 years, had ≥1 prescription for a target OAB drug (between 1 
May 2013 and 29 June 2014) and 12 months of continuous enrolment before and after 
the index prescription date. 
In this study, patients prescribed Mirabegron were significantly more likely to continue 
treatment long term than those prescribed Tolterodine ER with 12-month persistence 
rates of 37.7% and 20.2%, respectively, and median times to discontinuation of 169 
days and 56 days, respectively. Persistence with Mirabegron was also significantly 
better with each of the other nine antimuscarinics commonly prescribed in the UK. 
These improvements in persistence were also maintained in the predefined sub-
cohorts of treatment-naïve, treatment-experienced and older patients, as well as after 
matching to control for potentially confounding differences in baseline characteristics. 
The superior persistence of Mirabegron is supported with other recent real world 
evidence studies under different healthcare systems in the US, Japan, and Canada 
(Wagg et al., 2015; Nitti et al., 2016; Ogihara   et al., 2014).  
Persistence and adherence in this context may serve as a good proxy for 
efficacy/safety balance that leads to an improvement in quality of life due to symptom 
relief. The clinical significance has been highlighted in a prospective study which 
showed that women who adhered to OAB medication had significantly greater 
improvements in urinary symptoms compared with non-adherent women (Andy et al., 
2016).  However, due to the fact that this is a retrospective database study, one 
limitation of this study is that we are unable to examine the reasons for 
discontinuation.  
A large US survey of approximately 5000 respondents suggested that the most 
common reasons for discontinuation of antimuscarinics were related to efficacy 
(treatment did not work as expected), switching to a new medication, coping without 
medication and side effects (Benner et al., 2010). It is therefore feasible to assume that 
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the differences in early discontinuation between Mirabegron and antimuscarinics 
could be explained by the lack of anticholinergic side effects such as dry mouth. 
However, the gradient of the Kaplan-Meier curves was generally comparable after 3 
months, suggesting the reasons for later discontinuations may have been similar for 
both drug classes. Therefore, it is important to focus further research on trying to 
understand the reasons for discontinuation of OAB medications and how to support 
patients so they achieve long-term compliance.  
Some key strengths of this study are that it uses a large database (CPRD) and therefore 
a large population sample which is broadly representative of the UK population. Unlike 
RCT evidence that is collected in a controlled or often  idealised environment, and can 
often only measure efficacy in a limited population, thereby not providing a true 
indication of effectiveness, this study provides real world evidence demonstrating the 
effectiveness of Mirabegron. The study design also uses matching to control for 
baseline imbalances, notably the proportion of treatment-experienced patients which 
was greater in the Mirabegron-cohort at baseline. The main study limitations were the 
retrospective design and the use of prescription-event data rather than patient-
derived data to estimate outcomes such as patient diaries. The inability to capture 
reasons for discontinuations as mentioned earlier, as well as potential health benefits 
resulting from increased persistence  in terms of symptom severity and health related 
quality of life (HRQoL) were other limitations of this study. Also the prescribing of 
Mirabegron came relatively later than Tolterodine ER due to launch in February 2013 
and the release of updated guidelines even later, which may explain the reason for the 
higher proportion of treatment-experienced patients in the Mirabegron cohort.  
The analysis of the healthcare resource use was not reported here due to the 
unavailability of the HES data at the time of this analysis. This will be important data 
especially when estimating the economic impact of better persistence and adherence. 
There are also large prospective observational studies of Mirabegron on-going in the 
US (PERSPECTIVE; ClinicalTrials.gov.NCT02386072) and Europe (BELIEVE; 
ClinicalTrials.gov NCT02320772), which will include persistence and HRQoL outcomes 
in a real-life setting. These studies will yield important information on the impact of 
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treatment on patient’s quality of life in the real world setting and will provide more 
insights in to the reasons for patient discontinuations.  
 
6.3   Economic Impact of Mirabegron versus Antimuscarinics for the Treatment of 
Overactive Bladder in the UK. 
http://dx.doi.org/10.1007/s41669-017-0011-x 
 
The previous section (Chapter 6, section 6.2) discussed the impact of treatments for 
OAB in the real-world setting. In particular, the paper focussed on persistence and 
adherence as potential proxy’s to efficacy and safety balance in the real world. Also as 
highlighted in the models discussed in Chapter 5, persistence was an important driver 
of value (cost-effectiveness) in OAB. These models were largely based on data from 
the RCTs and real world data that did not include Mirabegron (pre-launch). As such the 
assumptions were conservative because in the base case models the persistence of 
Mirabegron was assumed to be similar to antimuscarinics (solifenacin). The previous 
models were also largely developed from the payer perspective. This model (Paper 9) 
therefore provides the opportunity to estimate the economic and clinical impact of 
using Mirabegron 50mg versus antimuscarinics agents  from a societal perspective by 
largely employing real-world data (specifically persistence rates) that includes 
Mirabegron 50mg. In section 6.1, the persistence rates for Mirabegron were superior 
compared to other antimuscarinics (range 8-25%), but what does this improved 
persistence mean in terms of economic and clinical impact from a payer and societal 
perspective? Thus, a Markov model was developed in Microsoft Excel with a 12 month 
time horizon and monthly cycles. The model compared a hypothetical cohort of 100 
patients (Mirabegron versus antimuscarinics) and inputs included were real-world 
treatment patterns data, healthcare resource use and both direct and indirect costs 
(e.g. drug acquisition and productivity loss). Model outputs included patient 
disposition, healthcare resource use, drug acquisition costs and other treatment-
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related costs. The key aim of the model was to help understand and the value of 
improved persistence.  
The model demonstrates that a greater number of patients persist on treatment with 
Mirabegron versus antimuscarinics, fewer patients switched treatment and fewer 
work hours were lost. Although as expected Mirabegron had higher medication costs 
over the 12 months versus antimuscarinics, these costs were largely offset by savings 
attributed to other direct and indirect costs. This was partly attributable to a lower 
proportion of non-persisters and switchers, who had a higher demand for healthcare 
resources and higher pad use, compared with patients who persisted on treatment. 
The results suggest that a greater number of patients in the UK who receive 
Mirabegron will persist on first-line treatment versus antimuscarinics over 12 months 
resulting in more patients with likely controlled symptoms. This would have a 
beneficial effect on the UK healthcare system in terms of lower resource use and 
overall treatment and containment of costs. Also while improvements in work 
productivity and lower healthcare resource use have been cited as benefits of 
increased treatment persistence (Liu-Seifret et al., 2011; Kim et al., 2016), better 
persistence rates could also be expected to improve patient quality of life, likely due to 
increased symptom control and an increased ability to continue daily activities.  This 
model does not include the improvements likely to be seen in terms of quality of life 
(Herdman et al,. 2011). 
The main strengths of this model are that it uses real-world data, related to treatment 
of OAB and healthcare resource use in the UK, therefore the total costs derived for 
Mirabegron versus antimuscarinics are based on effectiveness rather than efficacy. 
However, the benefits of Mirabegron are dependent on key assumptions such as 12 
month persistence being independent of the dose received such as for Trospium and 
Tolterodine ER and IR (extended release and immediate release respectively), and 
patients switch treatment or undergo surgery  are assumed have controlled symptoms 
for the remainder of the time within the model. The time horizon of the model was 
only 12 months, mainly driven by the design of the retrospective database study 
(CPRD) discussed in the previous chapter. However, as OAB is a chronic condition a 
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longer time-horizon would have been beneficial in order to accurately estimate the 
economic and clinical benefits of long-term treatment. Another limitation is that the 
model did not include any indirect and direct clinical data for estimates of efficacy or 
health-related QoL and therefore some patient perspectives have not been captured. 
6.4   Chapter Summary 
The retrospective database study using the CPRD database demonstrated that patients 
on Mirabegron were significantly more likely to continue treatment long term than 
those prescribed antimuscarinics. These results are consistent in the general 
population and in subgroups, when baseline covariates have been adjusted and when 
using matched controls. The large database with a large sample size and the matching 
to control for baseline imbalances adds to the robustness of this study. 
The economic model based on the above study, uses persistence as a proxy for 
efficacy/safety balance and improvements in quality of life. The model is therefore 
based on real-world effectiveness and the results are consistent with previous models 
discussed in chapter 5. However, there are some limitations in terms of the shorter 
time horizon and the exclusion of indirect and direct clinical data for estimates of 
efficacy or HRQoL, and therefore some patient perspectives may not have been 
captured. 
In the final chapter, the aims of this thesis will be revisited and a summary of how 
these have been achieved using the 9 published papers. Recommendations for future 
research and conclusions drawn from the current research will also be included. 
Chapter 7:     Summary, Recommendations and Conclusions 
7.1   Summary 
The increasing demand by decision-makers for more robust evidence, in particular 
RWE to demonstrate the value of new products and technologies was highlighted in 
chapter 1. The lead causes of this have been unsustainable increases in healthcare 
expenditure as result of ageing population, emerging markets and advances in 
treatment. As a result, there has been a marked rise in barriers to entry or cost-
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containment measures, mainly through the emergence of HTA in many healthcare 
systems (Volker et al., 2017). 
It is discernible that due to the ageing population chronic conditions will need to be 
prioritised by healthcare systems across the world. However, due to the non-life 
threatening nature of OAB there is a danger that this may not be prioritised in the 
same way as perhaps other chronic conditions.  
The aim of this thesis was to assess the extent to which cost-effectiveness of a recently 
launched drug in the treatment of overactive bladder is supported by RWE. Through 
the critical review of nine publications, the cost-effectiveness of Mirabegron was 
supported by RWE, especially with respect to persistence and adherence to treatment 
Each paper was used to demonstrate a concept of value and how this contributes to 
developing the overall value proposition for a new drug both in the pre-launch or pre-
HTA submission phase and in the post-launch phase. The thesis highlights how these 9 
publications form important building blocks to demonstrate the value of a new 
technology, and often submitted to decision makers to inform reimbursement 
decisions.  
7.2   Implications of the Thesis 
The thesis highlights the economic and humanistic burden of the disease and the 
unmet need in OAB with respect to current treatment options. Importantly, this work 
demonstrates the value of pharmacological treatments in OAB relative to each other 
using health economic evidence which includes RWE. The current body of work uses a 
range of clinical evidence, both RCT and RWE and NMA for comparative effectiveness 
purposes, several different modelling approaches in OAB and extensive PRO analyses 
which include both disease-specific and generic instruments. This adds rigor to how 
value has been assessed for pharmacological treatments in OAB. To date the value of 
pharmacological treatments in OAB may not have been evaluated with such 
completeness. The present thesis may also serve as a good template when developing 
evidence generation strategies in other therapy areas as well, especially in the current 
economic climate where decision makers are demanding that value is also 
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demonstrated in the real-world setting.  However, it must be noted that the thesis 
does not go as far as comparing the value of OAB relative to other chronic conditions. 
Although this is an interesting research question in the context of priority setting for 
payers and decision-makers, it was not within the scope of this research.  
The comparative effectiveness and safety research conducted through the NMA, 
although not without limitations, does provide good insights in to the value of OAB 
treatments relative to each other.  NMA’s have increased in importance over the last 
ten years as they utilise a larger network of evidence, both direct and indirect and are 
accepted by HTA bodies as an essential part of the evidence supporting the value of 
new technologies (Laws et al., 2014). In the absence of head-to-head studies this 
research aids comparative effectiveness and has been an integral part of 
reimbursement dossiers across Europe and Canada. The outputs from this NMA have 
also been applied to the HE models discussed in chapter 5, and have been included in 
HTA assessments in the UK (NICE, SMC, AWMSG) and adapted to other countries such 
as Sweden (TLV). As a result, Mirabegron is reimbursed in some of these countries at 
an acceptable price. Overall, the four articles on HE modelling in OAB included in this 
thesis (Chapter 5 and Chapter 6) appeal to both National and Local decision-makers in 
terms of demonstrating the relative value of OAB treatments and aiding with 
guidelines, reimbursement and pricing decisions. Finally, with respect to PRO’s the 
research highlights the significant impact OAB has on patients HRQoL and clinically 
meaningful improvements seen through treatment with Mirabegron. OAB is not a life 
threatening condition and therefore not always at the forefront of the mind of payers 
and decision-makers, which is why evidence related to patients HRQoL, is pivotal to 
understanding the value of treatments used in OAB. The present research 
demonstrates that the small changes seen in efficacy during the pivotal trials are 
actually meaningful to the patient as reflected by the PRO analyses and subsequent HE 
modelling (ICERs). The objective measures are thus supported by the subjective 
measures thereby strengthening the overall value arguments for Mirabegron. 
7.3    Limitations of the Thesis 
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There are some limitations of the current thesis. Regarding the PRO analyses, these are 
limited to the 12-week duration of the registration trials so long term impact of QoL 
cannot be assessed. These studies were not powered to detect differences compared 
to the active control, Tolterodine. There is also a large placebo effect which may water 
down the treatment effect and high ceiling effect with respect to EQ-5D.  Finally, the 
HRQoL analysis is based only on the 12 week RCTs and the current research does not 
include any QoL data from RWE.   
The retrospective design of the UK CPRD study and the fact that QoL data is not 
routinely collected in primary or secondary care means that the patient perspective in 
the real world is not fully captured.  Future research needs to focus on prospective 
collection of QoL data in a real world setting and preferably for longer than 12 weeks.  
Another key issue this research raises with respect to OAB is the generally low 
persistence observed with OAB medications. The CPRD analysis confirms that 
persistence with OAB medications is one of the lowest amongst major chronic 
conditions (Yeaw et al., 2009) but this research does not shed any light on the reasons 
for discontinuation. Independent research around the reasons for discontinuation 
have already been cited (Benner et al., 2010; Campbell et al.,2008; Cramer et al., 2008; 
Dmochowski et al.,2007; Krhut et al.,2014; Schabert et al., 2009). However, more 
qualitative research is required in this area in order to obtain a better understanding of 
why patients discontinue especially within the first 1-3 months. Also the definitions of 
persistence and adherence are confined to the rules set within the retrospective 
design of the study and the limitations of using a database. Therefore, there is a 
possibility that we may not have accounted for patients who take their medication on 
a PRN (“pro re nata”, “as the thing is needed”) basis for example, or in patients with 
whom the disease may wax and wane and in patients who may experience a resolution 
of symptoms. Again, further insights from a prospectively designed observational study 
that includes all the main pharmacological treatments available for OAB may 
complement the current thesis. 
Finally, the present research on the whole is focussed on demonstrating the value of 
OAB treatments in the general OAB population. One reason for this is that decision-
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makers currently do not recognise any subgroups in OAB as reimbursement or 
coverage is granted or not for the general OAB population with stipulations made on 
line of therapy, and not restricted to any subgroups. However, in some countries such 
as France, Germany and Italy the additional benefit of a medication like Mirabegron is 
currently not recognised and therefore not reimbursed. Subgroup analyses maybe a 
viable option in these countries.  
7.4    Recommendations for Further Studies/Research 
Based on the findings from this thesis several recommendations can be made as to 
where future research should be focussed to further enhance our understanding 
around the value of OAB medications.  
With respect to PRO’s, the EQ-5D-5L version is now available which has five response 
levels for each of the five dimensions of the EQ-5D. This may provide some further 
insights in to the sensitivity of the EQ-5D instrument to subtle changes in OAB 
symptomology. A 12-month, prospectively designed observational study using the EQ-
5D-5L and other disease specific PRO instruments such as the OAB-q, would be ideal in 
understanding the impact on HRQoL of treatments for OAB in the real world. Although 
not part of this research, prospective observational studies are now in progress in both 
the US (PERSPECTIVE; ClinicalTrials.gov.NCT02386072) and Europe (BELIEVE; 
ClinicalTrials.gov NCT02320772) which will yield important information on the long-
term impact of OAB treatments on HRQoL in the real world setting. This type of study 
design would complement the current research and may provide an accurate 
assessment of persistence and adherence to medication in the real world setting.  They 
would also provide more insights in to the reasons patient continue or discontinue 
OAB medications. 
Regarding the cost-utility analyses presented in chapter 5, the accuracy of these 
analyses may be improved if these were updated with the most up-to-date RWE that 
now includes Mirabegron (that is the CPRD study). Also, once the HRQoL data is 
available from the observational studies mentioned above, the cost-effectiveness 
model based on persistence presented in chapter 6 should also be updated to a cost-
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utlity analysis. Such a cost-utility analysis, based purely on RWE would make for an 
interesting comparison with the cost-utility analysis based mainly on RCT evidence. 
The ICERs generated from both models would provide important insights in to the 
cost-effectiveness of OAB medications and how this translates in to the real-world 
setting, and would complement the current research.  
RWE can also provide greater insights in to why such a large proportion of OAB 
patients discontinue medication. Understanding these reasons could help modify 
clinical practice such as more education for patients and better management of 
expectations. To this end more qualitative research is warranted. The knowledge 
Transfer Partnership (KTP) between Astellas and Manchester Metropolitan University 
has been set up recently to answer precisely this question. This is qualitative research 
that will conduct interviews with OAB patients in the UK who will be selected on the 
basis that they match the baseline characteristics of patients who have discontinued 
treatment within the first 3 months, versus a group who have continued taking their 
OAB medication for at least 12 months. In addition, the patients from the current 
CPRD study will also be similarly selected to administer a series of PRO’s on-line.   
Finally, this thesis has highlighted analyses conducted across various subgroups. 
However, the main focus has still been on the general OAB population. The need to 
focus on specific subgroups of patients has been highlighted by negative 
reimbursement decisions in Germany and France for example and regular price 
reviews in Sweden and Spain. The KTP program mentioned above will also try and 
address this issue by focussing on specific sub-groups such as the elderly (anti-
cholinergic burden), neurogenic detrusor overactivity (NDO) patients, and on patients 
requiring an add-on or combination treatment.  
7.5    Conclusions 
In conclusion, the research presented in this thesis demonstrates that the cost-
effectiveness of a recently launched drug in the treatment of OAB (Mirabegron) is by 
and large supported by RWE. However, some limitations of the current evidence may 
be complemented through prospectively designed observational studies to capture 
62 
 
HRQoL and other elements such as persistence and adherence in the real world setting. 
There is also an opportunity to build on the current work through qualitative research 
that would help to understand the reasons for early discontinuation of treatment by 
patients and may help modify current clinical practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
Aballéa S, Maman K, Thokagevistk K, Nazir J, Odeyemi IA, Hakimi Z, Garnham A, Toumi 
M. Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for 
the Treatment of Adults with Overactive Bladder in the United Kingdom. Clin Drug 
Investig 2015;35:83–93. 
Abrams P, Cardozo L, Khoury S, Wein A. Incontinence. 5th Edition. 2013. Available at: 
http://www.icud.info/PDFs/INCONTINENCE%202013.pdf [Accessed 22 January 2016]. 
 
Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, 
Laties A, Nathanson NM, Pasricha PJ, Wein AJ. Muscarinic receptors: their distribution 
63 
 
and function in body systems, and the implications for treating overactive bladder. Br 
J Pharmacol 2006;148(5):565-78. 
 
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, 
Victor A, Wein A; Standardisation Sub-Committee of the International Continence 
Society. The standardisation of terminology in lower urinary tract function: report 
from the standardisation sub-committee of the International Continence Society. 
Urology 2003;61(1):37-49. 
 
American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American 
Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate 
Medication Use in Older Adults. J Am Geriatr Soc 2015;63(11):2227-46. 
 
Andy UU, Arya LA, Smith AL, et al.. Is self-reported adherence associated with clinical 
outcomes in women treated with anticholinergic medication for overactive bladder? 
Neurourol Urodyn 2016;35:738-42. 
 
Annemans L; Kubin M; Wuppertal AG. Real-Life data: A growing need. 
https://www.ispor.org/News/articles/Oct07/RLD.asp 
 
Balkrishnan R, Bhosle MJ, Camacho FT, Anderson RT. Predictors of medication 
adherence and associated health care costs in an older population with overactive 
bladder syndrome: a longitudinal cohort study. J Urol 2006;175(3 Pt 1):1067-71. 
 
Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, Fanning K, Trocio 
JN, Brubaker L. Patient-reported reasons for discontinuing overactive bladder 
medication. BJU Int 2010;105(9):1276-82. 
 
Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of 
antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 
2012;62(6):1040-60. 
 
Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and 
the aging brain. Alzheimers Dement 2013;9:377-85. 
 
Campbell UB, Stang P, Barron R. Survey assessment of continuation of and satisfaction 
with pharmacological treatment for urinary incontinence. Value Health 
2008;11(4):726-32. 
Campbell NL, Boustani MA, Lane KA, Gao S, Hendrie H, Khan BA, Murrell JR, Unverzagt 
FW, Hake A, Smith-Gamble V, Hall K. Use of anticholinergics and the risk of cognitive 
impairment in .an African American population. Neurology 2010;75:152-159. 
 
Carrière I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, Ancelin ML. 
Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly 
general population: the 3-city study. Arch Intern Med 2009;169(14):1317-24. 
 
Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D. 
Long-term patterns of use and treatment failure with anticholinergic agents for 
overactive bladder. Clin Ther 2013;35(11):1744-51. 
 
64 
 
Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, 
Wagg A.. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in 
Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical 
Practice. (Accepted for publication Eur Urol) 
Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of 
antimuscarinic treatments on overactive bladder: an update of systematic review and 
meta-analysis. Eur Urol 2008;54:543-62. 
 
Chiu A-F, Huang M-H, Wang C-C, Kuo H-K. Prevalence and factors associated with 
overactive bladder and urinary incontinence in community-dwelling Taiwanese. Tzu 
Chi Med J 2012;24:56–60. 
 
Christel M. "Evidence" Trail Elusive. Applied Clinical Trials. June 30, 2014. Accessed at: 
http://www.appliedclinicaltrialsonline.com/evidence-trail-elusive-0. 
 
ClinicalTrials.gov. NCT02386072. A prospective, observational, multicentre study of 
patients following initiation of new course of treatment for overactive bladder (OAB) 
(PERSPECTIVE). Available at: https://clinicaltrials.gov/ct2/show/NCT02386072 
[Accessed29May 2016]. 
 
ClinicalTrials.gov.NCT02320773. A prospective non-interventional study in overactive 
bladder (OAB) patients prescribed Betmiga as part of routine clinical practice 
(BELIEVE). Available at: https://clinicaltrials.gov/ct2/show/NCT02320773 [Accessed 29 
May 2016]. 
 
Corcos J, Schick E. Prevalence of overactive bladder and incontinence in Canada. Can J 
Urol 2004;11(3):2278-84. 
 
Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of 
overactive bladder, incontinence and other lower urinary tract symptoms on quality 
of life, work productivity, sexuality and emotional well-being in men and women: 
results from the EPIC study. BJU Int 2008;101(11):1388-95. 
 
Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community 
prevalence of overactive bladder in the United States stratified by sex and age. 
Urology 2011a;77(5):1081-7. 
 
Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. The impact of 
overactive bladder on mental health, work productivity and health-related quality of 
life in the UK and Sweden: results from EpiLUTS. BJU Int 2011b;108(9):1459–71. 
 
Coyne KS, Sexton CC, Thompson C, Kopp ZS, Milsom I, Kaplan SA. The impact of OAB 
on sexual health in men and women: results from EpiLUTS. J Sex Med 
2011c;8(6):1603–15. 
 
Coyne KS, Margolis MK, Kopp ZS, Kaplan SA. Racial differences in the prevalence of 
overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) 
study. Urology 2012a;79(1):95-101. 
 
65 
 
Coyne KS, Sexton CC, Thompson CL, Clemens JQ, Chen CI, Bavendam T, Dmochowski R. 
Impact of overactive bladder on work productivity. Urology 2012b;80(1):97-103. 
Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, Chen CI, 
Quentin Clemens J. The prevalence of lower urinary tract symptoms (LUTS) and 
overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. 
Neurourol Urodyn 2013a;32(3):230-7. 
 
Coyne KS, Sexton CC, Clemens JQ, Thompson CL, Chen CI, Bavendam T, Dmochowski R. 
The impact of OAB on physical activity in the United States: results from OAB-POLL. 
Urology 2013b;82(4):799-806. 
 
Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of 
urgency urinary incontinence in the United States: a systematic review. J Manag Care 
Pharm 2014;20(2):130–40. 
 
Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and 
frequency on health-related quality of life in overactive bladder: results from a 
national community survey. Value Health 2004;7:455-63. 
 
Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. 
Medication compliance and persistence: terminology and definitions. Value Health 
2008;11(1):44-7. 
 
Cziraky M, Pollock M. Real-world evidence studies: Applied Clinical Trials. 
http://www.appliedclinicaltrialsonline.com/real-world-evidence-studies 
 
Darkow T, Fontes CL, Williamson TE. Costs associated with the management of 
overactive bladder and related comorbidities. Pharmacotherapy 2005;25(4):511–9. 
 
Deloitte. 2005 Global Healthcare outlook common goals, competing priorities. 
http://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-
Health-Care/gx-lshc-2015-health-care-outlook-global.pdf 
 
Desroziers K, Aballéa S, Maman K, Nazir J, Odeyemi I, Hakimi Z. Estimating EQ-5D and 
OAB-5D health state utilities for patients with overactive bladder. Health Qual Life 
Outcomes 2013;11:200. 
Devlin NJ, Parkin D, Browne J. Patient-reported outcomes  in the NHS: New methods 
for analysing and reporting EQ-5D data. Health Econ 2010;19:886-905. 
 
Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making  2: A 
generalized linear modelling  framework for pairwise and network meta-analysis of 
randomised controlled trials. Med Decis Making 2013; 33:607-17. 
 
Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making  3. 
Heterogeneity-subgroups, meta-regression, bias, and bias-adjustment. Med Decis 
Making 2013;33:618-40. 
 
Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United 
States: results of a national survey. Curr Med Res Opin 2007;23(1):65-76. 
 
66 
 
D’Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, switch rates among  
extended-release and immediate-release overactive bladder medications in a regional 
managed care plan. J Manag Care Pharm 2008;14:291-301. 
 
Eurich DT, Johnson JA, Reid KJ, Spertus JA: Assessing responsiveness of generic and 
specific health related quality of life measures in heart failure. Health Qual Life 
Outcomes2006, 4:89. 
 
Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, Coulton S, 
Katona C, Boustani MA, Brayne C. Anticholinergic medication use and cognitive 
impairment in the older population: the medical research council cognitive function 
and ageing study. J Am Geriatr Soc 2011;59(8):1477-83. 
 
Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, Pashos CL. 
Economic costs of overactive bladder in the United States. Urology 2010;75(3):526–32. 
 
Gormley EA, Lightner DJ, Faraday M, Vasavada SP; American Urological Association; 
Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of 
overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J 
Urol 2015;193(5):1572-80. 
 
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Crane PK, 
Larson EB. Cumulative use of strong anticholinergics and incident dementia: a 
prospective cohort study. JAMA Intern Med 2015;175(3):401-7. 
 
Hawken N, Hakimi Z, Aballéa S, Nazir J, Odeyemi IAO, Toumi M. Elicitation of health-
related quality-of-life concepts associated with overactive bladder: A qualitative study. 
J Health Econ Outcomes Res 2016, in press. 
 
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new 
five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727-1736. 
Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of medical 
therapies for overactive bladder in men and women: analysis of more than 7.2 million 
aging patients. Eur Urol 2010;57(4):586-91. 
 
Herschorn S, Gajewski J, Schulz J, Corcos J. A population-based study of urinary 
symptoms and incontinence: the Canadian Urinary Bladder Survey. BJU Int 
2008;101(1):52-8. 
Hershorn S, Barkin J, Castro-Diaz D, et al. A Phase 3 randomised, parallel group, 
placebo controlled, multicentre study to assess the efficacy and safety of the  
ß3adrenoceptor agonist Mirabegron in patients with symptoms of overactive bladder. 
Urology 2013;82:313-20. 
 
Homma Y, Yamaguchi O, Hayashi K; Neurogenic Bladder Society Committee. An 
epidemiological survey of overactive bladder symptoms in Japan. BJU Int 
2005;96(9):1314-8. 
 
Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Piancentini A, Stewart WF, Corey R, Zhou 
SZ, Hunt TL. Estimated economic costs of overactive bladder in the United States. 
Urology 2003;61(6):1123-8. 
67 
 
 
Inoue S, Kobayashi M, Sugaya K. Economic impact of overactive bladder symptoms in 
Japan. Nihon Hinyokika Gakkai Zasshi 2008;99(7):713-22. Japanese. 
 
Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, 
Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, 
overactive bladder, and other lower urinary tract symptoms in five countries: results 
of the EPIC study. Eur Urol 2006a;50(6):1306–14. 
 
Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder 
symptoms on employment, social interactions and emotional well-being in six 
European countries. BJU Int 2006b;97(1):96-100. 
 
Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact 
of overactive bladder syndrome in six Western countries. BJU Int 2009;103(2):202–9. 
 
Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of 
lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder 
outlet obstruction. BJU Int 2011;108(7):1132-8. 
 
Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner T.  Healthcare resource use 
and costs of privately insured patients who switch, discontinue, or persist on anti-
muscarinic therapy for overactive bladder.  J Med Econ 2014;17(10):741-50. 
Kaplan W, Laing R. Priority medicines for Europe and the World. Nov 2004. World 
health organisation. Department of essential drugs and medicines policy. 
http://m.tipharma.com/fileadmin/user_upload/Documenten/PDF/WHO_EDM_PAR_2
004.7.pdf 
 
Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of Mirabegron , a 
ß3adrenoceptor agonist in patients with overactive bladder: results from a European-
Australian randomised phase 3 trial Eur Urol 2013;63:283-95. 
 
Khullar V, Amarenco G, Angulo JC, Blauwet MB, Nazir J, Odeyemi IA, Hakimi Z. Patient-
reported outcomes with the β3 -adrenoceptor agonist mirabegron in a phase III trial in 
patients with overactive bladder. Neurourol Urodyn 2015. [Epub ahead of print] 
 
 
Kim TH and Lee KS: Persistence and compliance with medication management in the  
treatment of overactive bladder. Investig Clin Urol 2016; 57:84 
 
Klotz T, Brüggenjürgen B, Burkart M, Resch A. The economic costs of overactive 
bladder in Germany. Eur Urol 2007;51(6):1654-62. 
 
Kobelt G, Jonsson L, Mattiason A. Cost-effectiveness of new treatments for overactive 
bladder: the example of Tolterodine, a new muscarinic agent: a Markov model. 
Neurourol Urodyn. 1998;17:599-611. 
 
68 
 
Koyama A, Steinman M, Ensrud K, Hillier TA, Yaffe K. Ten-year trajectory of potentially 
inappropriate medications in very old women: importance of cognitive status. J Am 
Geriatr Soc. 2013;61:258-63. 
 
Krhut J, Gärtner M, Petzel M, Sykora R, Nemec D, Tvrdik J, Skoupa J. Persistence with 
first line anticholinergic medication in treatment-naïve overactive bladder patients. 
Scand J Urol 2014;48(1):79-83 
 
Laws A, Kendall R, Hawkins N. Comparison of National Guidelines for Network Meta-
Analysis. Value in Health 17 (2014)642-654. 
 
Laws A, Kendall R, Hawkins N. A  Comparison of National  Guidelines for Network 
Meta-Analysis.. Value in Health 17 (2014)642-654 . 
 
Lee YS, Lee KS, Jung JH, Han DH, Oh SJ, Seo JT, Lee JG, Park HS, Choo MS. Prevalence 
of overactive bladder, urinary incontinence, and lower urinary tract symptoms: 
Results of Korean EPIC study. World J Urol 2011a;29(2):185–90. 
 
Lee KS, Choo MS, Seo JT, Oh SJ, Kim HG, Ng K, Lee KJ, Tan JT, Kim JC. Impact of 
overactive bladder on quality of life and resource use: results from Korean Burden of 
Incontinence Study (KOBIS). Health Qual Life Outcomes 2015;13:89. 
 
Lee YS, Choo MS, Lee JY, Oh SJ, Lee KS. Symptom change after discontinuation of 
successful antimuscarinic treatment in patients with overactive bladder symptoms: a 
randomised, multicentre trial. Int J Clin Pract 2011b;65(9):997-1004. 
 
Lee GJ, Hong JY, Choo MS et al. Tolterodine: as effective but better tolerated than 
oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol 
2002:9:247-52. 
 
Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults 
with symptoms of overactive bladder: results from U.S. community-based  survey. 
Urology 2001;57:1044-50. 
 
Liu-Seifret H, Ascher-Svanum H, Osuntokun O et al: Change in level of productivity in 
the treatment of schizophrenia with olanzapine or other antipsychotics. BMC 
Psychiatry 2011;11:87. 
Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 
2002;21:2313-24. 
Lucas MG, Bedretdinova D, Berghmans LC, et al. Guidelines on urinary incontinence 
2015. European Association of Urology [Internet]. Available at: http://uroweb.org/wp-
content/uploads/EAU-Guidelines-Urinary-Incontinence-2015.pdf [Accessed 22 January 
2016] 
 
Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z. 
Comparative efficacy and safety of medical treatments for the management of 
overactive bladder: a systematic literature review and mixed treatment comparison. 
Eur Urol 2014;65:755–65. 
69 
 
Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are 
the symptoms of an overactive bladder and how are they managed? A population-
based prevalence study. BJU Int 2001;87(9):760–6. 
 
Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive 
bladder symptoms on health-related quality of life, anxiety, depression, and 
treatment seeking in the United States: results from EpiLUTS. Urology 2012;80(1):90–
6. 
 
Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo 
for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006 Oct 
18;(4):CD003781. 
 
National Institute for Health Care and Excellence. Urinary incontinence: the 
management of urinary incontinence in women. NICE clinical guideline 171. 
September 2013. Available at: https://www.nice.org.uk/guidance/cg171 [Accessed 22 
January 2016] 
 
Nazir J, Posnett J, Walker A, Odeyemi IA, Hakimi Z, Garnham A. Economic evaluation of 
pharmacological treatments for overactive bladder from the perspective of the UK 
National Health Service. J Med Econ 2015;18:390–7. 
Nazir J, Maman K, Neine ME, Briquet B, Odeyemi IA, Hakimi Z, Garnham A, Aballéa S. 
Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the 
Treatment of Adults with Overactive Bladder in the United Kingdom. Value Health 
2015;18:783–90 
Nazir J,  Berling M, McCrea C, Fatoye F, Bowditch S, Hakimi Z, Wagg A.  Economic 
Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder 
in the UK. Accepted for publication in PharmacoEconomics-Open. 
 
Nicolson P, Kopp Z, Chapple CR, Kelleher C. It's just the worry about not being able to 
control it! A qualitative study of living with overactive bladder. Br J Health Psychol 
2008;13(Pt 2):343-59 
 
NICE: Guides to methods of health technology appraisal. London: National Institute of 
Health and Clinical Excellence, 2008. 
 
Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of 
overactive bladder.: A pre-specified pooled efficacy analysis and pooled safety 
analysis of three randomised, double-blind, placebo controlled, phase 3 studies. Int J 
Clinical Prac 2013;67:619-32. 
 
Nitti VW, Rovner ES, Franks B , et al. Persistence with Mirabegron versus Tolterodine 
in patients with overactive bladder. Am J Pharm Benefits 2016; 8:e25-e33. 
 
Oefelein MG. Safety and tolerability profiles of anticholinergic agents used for the 
treatment of overactive bladder. Drug Saf 2011;34(9):733-54. 
 
Ogihara K, Kaguyama H, Sakamoto H, et al. Persistence with Mirabegron in patients 
with overactive bladder: a comparative study of Mirabegron and antimuscarinics. 
70 
 
International Continence Society (ICS) 2014, 20-24 October 2014, Rio de Janeiro, 
Brazil. Abstract 576. 
 
O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START 
criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 
2015;44(2):213-8. 
 
Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD. The total 
economic burden of overactive bladder in the United States: a disease-specific 
approach. Am J Manag Care 2009;15(4 Suppl):S90-7. 
 
Parkin D, Rice N, Devlin N. Statistical analysis of EQ-5D profiles: does the use of value 
sets bias inference? Med Decis Making 2010;30:556-65 
 
Pavesi M, Devlin N, Hakimi Z, Nazir J, Herdman M, Hoyle C, Odeyemi IA. Understanding 
the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-
5D clinical trial data for mirabegron. J Med Econ 2013;16:866–76.  
Reeves P, Irwin D, Kelleher C, Milsom I, Kopp Z, Calvert N, Lloyd A. The current and 
future burden and cost of overactive bladder in five European countries. Eur Urol 
2006(5);20:1050–7. 
 
Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive 
impairment, falls and all-cause mortality in older adults: A systematic review and 
meta-analysis. Br J Clin Pharmacol 2015;80(2):209-20. 
 
Schabert VF, Bavendam T, Goldberg EL, Trocio JN, Brubaker L. Challenges for 
managing overactive bladder and guidance for patient support. Am J Manag Care 
2009;15(4 Suppl):S118-22. 
 
Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne 
KS. Persistence and adherence in the treatment of overactive bladder syndrome with 
anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 
2011;65(5):567-85. 
 
Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner TH. Impact of overactive 
bladder on work productivity in the United States: results from EpiLUTS. Am J Manag 
Care 2009(4 Suppl);15:S98-S107. 
 
Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne 
KS. Persistence and adherence in the treatment of overactive bladder syndrome with 
anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 
2011;65(5):567-85. 
 
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, 
Wein AJ. Prevalence and burden of overactive bladder in the United States. World J 
Urol 2003;20(6):327–36. 
 
Stolk EA, Busschbach JJ: Validity and feasibility of the use of condition-specific 
outcome measures in economic evaluation. Qual Life Res 2003, 12(4):363-371 
71 
 
Sung W, You H, Yoon TY, Lee SJ. Socioeconomic costs of overactive bladder and stress 
urinary: Incontinence in Korea. Intl Neurourol J 2012;16(1):23–9. 
 
Tang DH, Colayco DC, Khalaf KM, Piercy J, Patel V, Globe D, Ginsberg D. Impact of 
urinary incontinence on healthcare resource utilization, health-related quality of life 
and productivity in patients with overactive bladder. BJU Int 2014;113(3):484-91. 
 
Teloken C, Caraver F, Weber FA, Teloken PE, Moraes JF, Sogari PR, Graziottin TM. 
Overactive bladder: prevalence and implications in Brazil. Eur Urol 2006;49(6):1087-
92. 
 
Temml C, Heidler S, Ponholzer A, Madersbacher S. Prevalence of the overactive 
bladder syndrome by applying the International Continence Society definition. Eur 
Urol 2005;48(4):622–7. 
 
Thomas L, Culley EJ .Over-active bladder disease: The urge for better therapies. JMCP: 
May 2014;Vol14;No.4 p381-38 
 
Tikkinen KA, Tammela TL, Rissanen AM, Valpas A, Huhtala H, Auvinen A. Is the 
prevalence of overactive bladder overestimated? A population-based study in Finland. 
PLoS One 2007;2(2):e195. 
 
Volker R, Ruhl M, Thomas S.  Revitalising pharmaceutical R&D: The value of real world 
evidence..http://www.strategyand.pwc.com/reports/revitalizing-pharmaceutical-rd 
 
Vrijens D, Drossaerts J, van Koeveringe G, Van Kerrebroeck P, van Os J, Leue C. 
Affective symptoms and the overactive bladder - a systematic review. J Psychosom 
Res 2015;78(2):95-108. 
 
Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic 
therapy for overactive bladder: a UK experience. BJU Int 2012;110:1767-74. 
 
Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 
receptor agonist, Mirabegron, versus antimuscarinics in overactive bladder: Early 
experience in Canada. Can Urol Assoc J 2015;9:343-50. 
 
 
Wang Y, Xu K, Hu H, Zhang X, Wang X, Na Y, Kang X. Prevalence, risk factors, and 
impact on health related quality of life of overactive bladder in China. Neurourol 
Urodynamics 2011;30(8):1448–55. 
 
Wen JG, Li JS, Wang ZM, Huang CX, Shang XP, Su ZQ, Lu YT, Suo ZH, Wang Y, Qin GJ, 
Zhang WX, Heesakkers JP. The prevalence and risk factors of OAB in middle-aged and 
old people in China. Neurourol Urodynamics 2014;33(4):387–91. 
 
Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees 
with overactive bladder: work loss burden. J Occup Environ Med 2005;47(5):439-46. 
 
Yang Y, Brazier J, Tsuchia A, Coyne K. Estimating a preference-based single index from 
the overactive bladder questionnaire. Value Health 2009, 12(1):159-166. 
72 
 
 
Yeaw J, JS Benner, JG Walt, S Silan, DB Smith. Comparing Adherence and Persistence 
Across 6 Chronic Medication Classes. Journal of Managed Care Pharmacy. 2009:Vol 
15:9:p728-740 
 
Young T, Yang Y, Brazier JE, Tsuchia A, Coyne K: The first stage of developing 
preference-based measures: Constructing a health-state classification using Rasch 
analysis. Qual Life Res 2009, 18(2):253-265. 
 
Yu HJ, Liu CY, Lee KL, Lee WC, Chen TH. Overactive bladder syndrome among 
community-dwelling adults in Taiwan: Prevalence, correlates, perception, and 
treatment seeking. Urol Int 2006;77(4):327–33. 
 
 
 
Appendices 
 
 
Appendix   A:     Peer Reviewed Publication List 
 
Appendix   B:     Declaration of Contributions 
 
 
 
Appendix A:  Peer Reviewed Publication List 
 
Papers included in this thesis are marked with an asterix. 
 
Hart WM, Nazir J, Baskin-Bey E. An incidence model of the cost of advanced 
prostate cancer in Spain. J Med Econ 2014;17:125–31 
*Desroziers K, Aballéa S, Maman K, Nazir J, Odeyemi I, Hakimi Z. Estimating EQ-
5D and OAB-5D health state utilities for patients with overactive bladder. 
Health Qual Life Outcomes 2013;11:200. 
Hart WM, Abrams P, Munro V, Retsa P, Nazir J. Cost-effectiveness analysis of 
solifenacin versus oxybutynin immediate-release in the treatment of patients 
with overactive bladder in the United Kingdom. J Med Econ 2013;16:1246–54.  
*Pavesi M, Devlin N, Hakimi Z, Nazir J, Herdman M, Hoyle C, Odeyemi IA. 
Understanding the effects on HR-QoL of treatment for overactive bladder: a 
detailed analysis of EQ-5D clinical trial data for mirabegron. J Med Econ 
2013;16:866–76.  
73 
 
*Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, 
Hakimi Z. Comparative efficacy and safety of medical treatments for the 
management of overactive bladder: a systematic literature review and mixed 
treatment comparison. Eur Urol 2014;65:755–65. 
Nazir J, Hart WM. The cost-effectiveness of solifenacin vs. trospium in the 
treatment of patients with overactive bladder in the German National Health 
Service. J Med Econ 2014;17:408–14. 
Hakimi Z, Johnson M, Nazir J, Blak B, Odeyemi IA. Drug treatment patterns for 
the management of men with lower urinary tract symptoms associated with 
benign prostatic hyperplasia who have both storage and voiding symptoms: a 
study using the health improvement network UK primary care data. Curr Med 
Res Opin 2015;31:43–50. 
Mathias SD, Crosby RD, Nazir J, Klaver M, Drogendijk T, Hakimi Z, Odeyemi IA. 
Validation of the Patient Perception of Intensity of Urgency Scale (PPIUS) in 
Male Patients with Lower Urinary Tract Symptoms Associated with Benign 
Prostatic Hyperplasia. Value Health 2014;17:823–9. 
*Aballéa S, Maman K, Thokagevistk K, Nazir J, Odeyemi IA, Hakimi Z, Garnham 
A, Toumi M. Cost Effectiveness of Mirabegron Compared with Tolterodine 
Extended Release for the Treatment of Adults with Overactive Bladder in the 
United Kingdom. Clin Drug Investig 2015;35:83–93. 
*Nazir J, Posnett J, Walker A, Odeyemi IA, Hakimi Z, Garnham A. Economic 
evaluation of pharmacological treatments for overactive bladder from the 
perspective of the UK National Health Service. J Med Econ 2015;18:390–7. 
Leaper D, Nazir J, Roberts C, Searle R. Economic and clinical contributions of an 
antimicrobial barrier dressing: a strategy for the reduction of surgical site 
infections. J Med Econ 2010; 13: 447–52 
 
74 
 
*Nazir J, Maman K, Neine ME, Briquet B, Odeyemi IA, Hakimi Z, Garnham A, 
Aballéa S. Cost Effectiveness of Mirabegron Compared with Antimuscarinic 
Agents for the Treatment of Adults with Overactive Bladder in the United 
Kingdom. Value Health 2015;18:783–90 
Nazir J, Heemstra L, van Engen A, Hakimi Z, Ivanescu C. Cost-effectiveness of a 
fixed-dose combination of solifenacin and oral controlled adsorption system 
formulation of tamsulosin in men with lower urinary tract symptoms associated 
with benign prostatic hyperplasia. BMC Urol 2015;15:41. 
*Khullar V, Amarenco G, Angulo JC, Blauwet MB, Nazir J, Odeyemi IA, Hakimi Z. 
Patient-reported outcomes with the β3 -adrenoceptor agonist mirabegron in a 
phase III trial in patients with overactive bladder. Neurourol Urodyn 2015. 
[Epub ahead of print] 
Macdiarmid S, Al-Shukri S, Barkin J, Fianu-Jonasson A, Grise P, Herschorn S, 
Saleem T, Huang M, Siddiqui E, Stölzel M, Hemsted C, Nazir J, Hakimi Z, Drake 
MJ; BESIDE Investigators. Mirabegron as Add-on Treatment to Solifenacin in 
Incontinent Overactive Bladder Patients with an Inadequate Response to 
Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes 
from the BESIDE study. J Urol 2016 [Epub ahead of print] 
 
Watt M, McCrea C, Johal S, Posnett J, Nazir J.. A cost-effectiveness and budget 
impact analysis of first-line fidaxomicin for patients with Clostridium difficile 
infection (CDI) in Germany. Infection 2016 [Epub ahead of print] 
Asensio A, Di Bella S, Lo Vecchio A, Grau S, Hart WM, Isidoro B, Scotto R, 
Petrosillo N, Watt M, Nazir J. The impact of Clostridium difficile infection on 
resource use and costs in hospitals in Spain and Italy. International Journal of 
Infectious Diseases. Int J Infect Dis 2015;36:31–8 
75 
 
Drake MJ, Sokol R, Coyne K, Hakimi Z, Nazir J, Dorey J, Klaver M, Traudtner K, 
Odeyemi IA, Oelke M, van Kerrebroeck P; NEPTUNE study group. Responder 
and health-related quality of life analyses in men with lower urinary tract 
symptoms treated with a fixed-dose combination of solifenacin and tamsulosin 
oral-controlled absorption system: results from the NEPTUNE study. BJU Int 
2016;117:165–72 
Hawken N, Hakimi Z, Aballéa S, Nazir J, Odeyemi IAO, Toumi M. Elicitation of 
Health-Related Quality-of-Life Concepts Associated With Overactive Bladder: A 
Qualitative Study. [Accepted (JHEOR)] 
Khullar V, Amarenco G, Angulo JC, Blauwet MB, Nazir J, Odeyemi IA, Hakimi Z. 
Patient-reported outcomes with a β3 -adrenoceptor agonist mirabegron in a 
phase III trial in patients with overactive bladder. Value Health 2015;18:783–90 
Mankowski C, Ikenwilo D, Watson V, Ryan M, Heidenreich S, Newman C, Nazir J. 
Men’s preferences for the treatment of lower urinary tract symptoms 
associated with benign prostatic hyperplasia: A discrete choice experiment. 
Accepted www.dovepress.com . 
Hakimi Z, Herdman M, Pavesi M, Devlin N, Hakimi Z, Nazir J, Hoyle C, Odeyemi 
IAO. Using EQ-5D-3L and OAB-5D to assess changes in the health-related 
quality of life (HRQoL) of men with lower urinary tract symptoms (LUTS) 
associated with benign prostatic hyperplasia (BPH). Accepted for publication in 
Quality of Life Research. 
*Jameel Nazir,  Malin Berling, Charles McCrea,  Francis Fatoye,  Sally Bowditch,  
Zalmai Hakimi, Adrian Wagg.  Economic Impact of Mirabegron Versus 
Antimuscarinics for the Treatment of Overactive Bladder in the UK. Accepted 
for publication in PharmacoEconomics-Open. 
 
*Christopher R. Chapple MD, Jameel Nazir MSc, Zalmai Hakimi PharmD, 
Sally Bowditch MPH, Francis Fatoye PhD, Florent Guelfucci PhD, Amine Khemiri 
76 
 
MSc, Emad Siddiqui MD, Adrian Wagg MD. Persistence and Adherence with 
Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: 
A Retrospective Observational Study in UK Clinical Practice. (Accepted for 
publication Eur Urol ) 
 
 
 
 
 
 
 
 
 
Appendix   B:   Declaration of Contributions 
The table below summarises my percentage contribution towards each paper 
submitted in this thesis. The publications are cited in the order in which they 
are cited in the thesis. 
Number Publication Percentage 
contribution 
1 Khullar V, Amarenco G, Angulo JC, Blauwet MB, Nazir J, 
Odeyemi IA, Hakimi Z. Patient-reported outcomes with 
the β3 -adrenoceptor agonist mirabegron in a phase III 
trial in patients with overactive bladder. Neurourol 
40% 
77 
 
Urodyn 2015.DOI 10.1002/nau 
2 Pavesi M, Devlin N, Hakimi Z, Nazir J, Herdman M, 
Hoyle C, Odeyemi IA. Understanding the effects on HR-
QoL of treatment for overactive bladder: a detailed 
analysis of EQ-5D clinical trial data for mirabegron. J 
Med Econ 2013;16:866–76.  
40% 
3 Desroziers K, Aballéa S, Maman K, Nazir J, Odeyemi I, 
Hakimi Z. Estimating EQ-5D and OAB-5D health state 
utilities for patients with overactive bladder. Health 
Qual Life Outcomes 2013;11:200. 
40% 
4 Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, 
Siddiqui E, Odeyemi I, Hakimi Z. Comparative efficacy 
and safety of medical treatments for the management 
of overactive bladder: a systematic literature review 
and mixed treatment comparison. Eur Urol 
2014;65:755–65 
50% 
5 Aballéa S, Maman K, Thokagevistk K, Nazir J, Odeyemi 
IA, Hakimi Z, Garnham A, Toumi M. Cost Effectiveness 
of Mirabegron Compared with Tolterodine Extended 
Release for the Treatment of Adults with Overactive 
Bladder in the United Kingdom. Clin Drug Investig 
2015;35:83–93. 
50% 
6 Nazir J, Maman K, Neine ME, Briquet B, Odeyemi IA, 
Hakimi Z, Garnham A, Aballéa S. Cost Effectiveness of 
Mirabegron Compared with Antimuscarinic Agents for 
the Treatment of Adults with Overactive Bladder in the 
United Kingdom. Value Health 2015;18:783–90 
70% 
7 Nazir J, Posnett J, Walker A, Odeyemi IA, Hakimi Z, 
Garnham A. Economic evaluation of pharmacological 
treatments for overactive bladder from the perspective 
70% 
78 
 
of the UK National Health Service. J Med Econ 
2015;18:390–7. 
8 Christopher R. Chapple MD, Jameel Nazir MSc, Zalmai 
Hakimi PharmD, Sally Bowditch MPH, Francis Fatoye 
PhD, Florent Guelfucci PhD, Amine Khemiri MSc, Emad 
Siddiqui MD, Adrian Wagg MD. Persistence and 
Adherence with Mirabegron versus Antimuscarinic 
Agents in Patients with Overactive Bladder: A 
Retrospective Observational Study in UK Clinical 
Practice. (Accepted for publication Eur Urol ) 
 
60% 
9 Jameel Nazir,  Malin Berling, Charles McCrea,  Francis 
Fatoye,  Sally Bowditch,  Zalmai Hakimi, Adrian Wagg.  
Economic Impact of Mirabegron Versus 
Antimuscarinics for the Treatment of Overactive 
Bladder in the UK. Accepted for publication in 
PharmacoEconomics-Open. 
80% 
 
